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1.1. HISTORICAL BACKGROUND 
Since the very frrst historical records, urethral discharge and dysuria have been 
reported [1,2]. These conditions were already described in ancient Egyptian and 
Hebrew writings. Hippocrates mentioned urethral discharge in the same breath as 
other genital diseases. At that time, no distinction was made between various genital 
diseases. The term gonorrhea which meant 'flow of seed~ (genus, "'seed'". and rhoea, 
"flow") was frrst introduced by Hirsch. Initially, gonorrhea was considered as a 
benign form of syphilis. In 1554, Feme!, in his book 'Medicina', described 
gonorrhea as an infection of the urinary bladder and distingnished it as such from 
syphilis. Sylvius (1614-1672) thought, that the prostate was the organ affected. At 
the same time, DeGraaf (1641-1673) postulated that the disease was located in the 
prostate and the testes. Cowper (1666-1709) concluded, that the cause was present 
in the small urethral glands he had discovered. In 1689, Musitanus described 
gonorrhea as an inflammation of the urethra. In 1765, Hunter inoculated himself 
with infected material from a patient with urethral discharge in order to prove, that 
syphilis and gonorrhea had separate clinical presentations. After this experiment, he 
suffered both from syphilis and gonorrhea. In the years 1831-1837, Ricard 
conclusively demonstrated, that gonorrhea, chancroid and syphilis were clearly 
separate diseases on the basis of numerous experimental inoculations in humans. He 
postulated, that the aetiologic causes were either an irritation of the urethra due to 
prolonged sexual excitement and/or some substances causing irritation of mucous 
membranes. In 1879, Neisser identified the agent causing gonorrhea. In 1880, 
Leistikow successfully cultured the microbe in vitro and it became clear, that there 
were various forms of urethritis. Gonococcal and non-gonococcal urethritis could be 
distingnished. It was observed that N. gonorrhoeae could not be cultured or 
demonstrated in Gram-stained preparations from some patients with urethritis. The 
commonly prescribed anti-gonococcal therapies for that time were also ineffective 
in these patients. At the beginning of the twentieth century, intracytoplasmic 
inclusion bodies, which are still today regarded as characteristic for the presence of 
Chlamydiae, were observed in smears of urethral exudates from patients with 
urethritis. In 1954, U. urealyticum was shown to be one of the causative agents of 
urethritis [3]. In 1965, it became possible to culture C. trachomatis in cell cultures 
[4]. 
The treatment of urethritis prior to 1935, the year in which sulpha preparations 
became commercially available, was disappointing. The first therapies of urethritis 
comprised urethral irrigations and bringing into the urethra pegs and threads 
(bougies), which were drenched in aluin, zinc sulphate, lead acetate and tannin 
solutions. These substances had some anti-inflammatory effect on the mucous 
membranes, but failed to eliminate the cause. 
In the nineteenth century, the treatment consisted of santa oil and copaivabalsam 
given orally. These treatments, however, were not very effective. Once the agent 
causing gonorrhea had been identified and isolated, the treatment consisted of local 
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application of antiseptic solutions of silver salts such as silver nitrate and protargol. 
During a short period prior to the second world war, gonococcal infections were 
treated with sulpha preparations. 
The development of resistance by the gonococci to sulpha preparations soon 
rendered this therapy ineffective [5]. Once penicillin became available in 1945, 
gonococcal urethritis could be treated effectively. Non-gonococcal urethritis could 
be effectively treated only after tetracyclines and macrolides were introduced. 
The knowledge about the aetiology of urethritis in men has expanded significantly 
in recent years. At present, sexually transmitted and not-sexually transmitted 
urethritis can be distinguished. Sexually transmitted urethritis in turn, can be sub-
divided into gonococcal and non-gonococcal urethritis. A review of such a 
classification scheme is provided in Table I. 
1.2 GONOCOCCAL INFECTIONS 
Gonorrhea is caused by N. gonorrhoeae which belongs to the genus Neisseria of 
the family Neisseriaceae. Neisseriae are nonmotile, nonspore-forming, Gram-
negative diplococci. In Gram-stained preparations, N. gonorrhoeae appear as orange-
red coffee bean-shaped or kidney-shaped diplococci. 
Humans are the only natural host of N. gonorrhoeae. A snitable animal model for 
investigating gonococcal infections is not yet available [67]. To date, all attempts 
to develop vaccines against N. gonorrhoeae have been unsuccessful [68]. The main 
emphasis of research activities at present is on in vitro and in vivo studies of N. 
gonorrhoeae and on the interactions between N. gonorrhoeae and its host. 
Gonococcal infections can be divided into symptomatic and asymptomatic, acute 
and chronic infections with a complicated or an uncomplicated course. The clinical 
spectrum encompasses on the one hand a full-blown clinical presentation and on the 
other hand a completely asymptomatic course. Between these two poles many 
Table 1. Aetiology of urethritis in males. 
sexually transmitted urethritis 
gonococcal: 
non-gonococcal: 
Neisseria gonorrhoeae 
Chlamydia trachomatis (35-60%) * 
Ureaplasma urealyticum (10-40%) * 
Neither (25-50%) * 
Trichomonas vaginalis, (rare) 
Yeast, (rare) 
Herpes simplex virus, (rare) 
Other bacteria ('?) 
not sexually transmitted urethritis 
allergic 
iatrogenic 
traumatic 
local proces: like tumors, strictures 
psychogenic '? 
phimosis 
symptom by other disease: 
Stevens Johnson Syndrome, erythema 
multiforme 
* percentages of total number of cases of non-gonococcal urethritis. 
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variegations are possible. Uncomplicated gonorrhea is defmed as a gonococcal 
infection which is confmed to the inoculation site(s). 
In me~ the clinical presentation may consist of an anterior urethritis, a proctitis 
and or an infection of the oropharynx. 
Acute anterior urethritis is the most conunon form of gonorrhea in men. The 
incubation period ranges from I to 14 days or longer. In 82% of the individuals, the 
complaints develop within 2 to 5 days [ 6]. The predominant symptoms are dysuria 
and mucopurulent discharge. fu most patients, the discharge becomes very profuse 
within 24 hours after onset and is accompanied by erythema and oedema of the 
urethral meatus [7]. One-quarter of the patients shows minimum symptoms which 
are clinically indistinguishable from those of other forms of urethritis [8,9]. There 
are also an estimated I to 2% asymptomatic carriers [10,11]. The usual course of 
untreated gonococcal urethritis is spontaneous resolution within several weeks and 
more than 95% of the patients become asymptomatic after six months. lt is highly 
unlikely that spontaneous resolution leads to subsequent asymptomatic carriage of 
N. gonorrhoeae. 
Anorectal infections in men are only observed in homosexuals and are attributed 
to a direct inoculation via rectal sexual intercourse. 
In 35 to 50% of the homosexual men with gonococcal urethritis the rectal mucosa 
is also infected [12]. Solitary rectal infections were observed in 40% of 815 
homosexual men that were investigated [12,13,14]. The symptoms ranged from 
minimal anal pruritis, painless mucopurulent discharge and anal bleeding to 
symptoms of fulminant proctitis such as tenesmus, severe pain in the rectum and 
constipation. Often, abnormalities are not externally visible and proctoscopy is 
required. In 36% to 62% of the men, rectal gonococcal infection follows an 
asymptomatic course [15,16]. Additioual gonococcal infection of the pharynx is also 
observed in 3% to 7% of heterosexual men and in 10% to 25% of homosexual men 
suffering from gonorrhea. A solitary pharyngeal gonococcal infection occurs in less 
than 5% of the patients irrespective of their sexual orientation [16-19]. Gonococcal 
infection of the pharynx occurs upon orogenital sex and is more efficiently 
transmitted via fellatio than via cunnilingus [17,20]. More than 90% of the 
oropharyngeal infections are asymptomatic [17,19,21]. Occasioual reports suggest 
that gonococcal infections of the oropharynx can cause acute pharyngitis or 
tonsillitis with or without fever and cervical lymphadenopathy [ 17]. 
There is a possible increased risk of disseminated (septic) gonococcal infection 
in patients with pharyngeal gonorrhea, however the natural course resulting in a 
spontaneous cure in all cases within 12 weeks together with a min.llnum risk of N. 
gonorrhoeae being transmitted from this site suggest a limited epidemiological 
importance of this infection site [17,22,23]. The number of rectal and oropharyngeal 
gonococcal infections has decreased significantly in men due to change(s) in sexual 
behaviour, reduction in the number of sexual partners and the use of condoms (safe 
sex) to prevent infection with Human lnununodeficiency Virus [24]. 
The complications of gonorrhea can be divided into four groups. The first group 
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consists of additional infections in the structures in the immediate vacinity. Infection 
of the Tyson's glands belongs to this group. This complication is rarely observed in 
the industrialized nations. Infection of the Littre's glands is relatively frequent. 
Another complication is abscess formation. A lymphangitis of the penis, sometimes 
accompanied by lymphadenitis is rare. 
Ascending infections from the urogenital region belong to the second group. 
Cowperitis, which is an abnormal complication, falls into this group. Symptoms 
include urinary urgency, pain in the perineum and pain at defaecation. An abscess 
may also form. An ascending infection may also cause a posterior urethritis and may 
ascend further, causing epididymitis. In 22% of 51 patients younger than 35 years 
suffering from epididymitis, N. gonorrhoeae was identified as the cause [25]. 
Epididymitis is generally unilateral. Secondarily, a hydrocele may develop and leave 
behind a fibrinous thickening after healing. Bilateral epididymitis occurs infrequently 
and may result in permanent sterility. Sometimes cystitis can occur, which may very 
occasionally ascend to the kidneys [26]. 
The third group consists of gonococcal infections outside the urogenital region, 
such as the gonococcal conjunctivitis, occurring via digital transmission. fu adults, 
such infections occur via auto-inoculation and are uncommon. Occasionally, such 
infections may occur in laboratory personnel working with N. gonorrhoeae [27]. 
One eye is usually involved. 
Disseminated gonococcal infections (DG!) belong to the fourth group. Approx-
imately 1 to 3% of the patients with mucosal gonorrhea develop DGI [28,29]. Prior 
to the introduction of antibiotics, DGI were frequently observed in men [30,31]. In 
the antibiotic era, this frequency has shifted towards women and homosexnal men 
probably as a result of asymptomatic infections in these two groups [28-36]. The 
clinical manifestations can be sub-divided into an initial bacteremia with accom-
panying skin lesions followed by a secondary phase in which septic arthritis occurs 
[32,34]. The clinical symptoms include fever, general malaise, skin lesions, 
tenosynovitis, polyarthralgies, polyarthritis, hepatitis and myopericarditis. Endo-
carditis, meningitis, perihepatitis, pnewnonia, osteomyelitis and adult respiratory 
distress syndrome are seldom. More than 90% of the patients have an arthropathy 
cr arthritis. These may be mild to purulent and sometimes follow a chronic course 
[37]. 
N. gonorrhoeae may spread into the general blood circulation from every site of 
infected mucosa. 
N. gonorrhoeae which have been isolated from blood or synovial fluid possess the 
following characteristics: they are of a transparent colony phenotype, are susceptible 
to penicill.in, require arginine, hypoxanthine and uracil for growth and are resistant 
to bactericidal action of serum and have a specific type of outer membrane protein 
I [38]. 
In some isolated cases, penicillinase producing N. gonorrhoeae were reported as 
the cause of DGI [39]. The host factors which play a role include a deficiency or 
an abnormality of one of the late-acting complement components (c5, c6, c7, c8), 
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hormonal factors in women, particularly, since DG! has been observed to occur 
premenstrually and during pregnancy [40-43]. In patients with DGI, circulating 
immunocomplexes have been detected which may be the possible cause of skin 
lesions and arthritis [32-35]. The differential diagnosis includes bacteremias as well 
as other types of reactive arthritis. 
The primary cutaneous infections belong to the particular forms of gonococcal 
infections. These infections occur mostly in genital ulcers and ulcers on the 
perineum, the upper legs and/or the fmgers [44-46]. Whether these infections are 
primary or secondary colonizations is not yet clear. 
At present, the ratio of gonorrhea in male to female is 1:1.5. 
The clinical spectrum of gonorrhea in women includes urethritis, cerv1crt1S, 
proctitis, acute Bartholinitis, conjunctivitis, endometritis, salpingitis, perihepatitis and 
DGL In premenarchal girls, N. gonorrhoeae can cause vulvitis and or vaginitis [!]. 
The symptoms of primary N. gonorrhoeae infection in women are less specific than 
in men and depend on the site of infection. The following symptoms are observed 
in women in whom gonorrhea has been diagnosed: vaginal discharge (cervicitis), 
dysuria and urinary urgency (urethritis or skenitis), pain in the vulva and swollen 
labia (acute Bartholinitis), abnormal uterine bleeding and lower abdominal 
tenderness with evidence of rebound (pelvic inflammatory disease). An ascending 
:infection from the cervix may lead to endometritis, salpingitis and peritonitis which 
are collectively also known as pelvic inflammatory disease (PID). Clinically, patients 
suffering from PID present with lower abdominal pain, mucopurulent cervical 
discharge and cervical motion tenderness upon vaginal touch. In the United States, 
the diagnosis of PID is made in 20% of the women with gonorrhea. Conversely, in 
40% of the women with PID, N. gonorrhoeae was observed to be the cause [1]. 
Perihepatitis, also called Fitz-Hugh-Curtis syndrome had also been mainly attributed 
to gonococcal infection, but more recent studies have shown that infection with C. 
trachomatis was frequently associated with this syndrome. The patients with this 
syndrome presents with an acute or subacute pain in the right upper quadrant of the 
abdomen, a mucopurulent cervicitis caused by N. gonorrhoeae or C. trachomatis or 
PID and/or a normal echography of the bile duct system. The risk of sterility after 
a single episode of salpingitis varies from 12 to 16%. 
The risk of ectopic pregnancy after a single episode of salpingitis is increased 
seven-fold. A single episode of gonococcal salpingitis resulted in occluded tubae in 
24% of the patients. 
Ophthalmia gonorrhoica neonatorum occurs more frequently than gonococcal 
infection of eyes in adults. The exact risk of genito-ocular transmission from a 
mother with genital gonococcal infection to her child is not lmown, but is estimated 
at 2% [47]. The clinical manifestation occurs 1 to 12 days after delivery. If left 
untreated, blindness can result [48]. 
The susceptibility-site for antibiotics and the mechanism(s) for developing 
resistance are generally the same for N. gonorrhoeae, E. coli and other Gram-
negative and many Gram-positive bacteria. After the introduction of sulphonamides 
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in 1935 to treat gonococcal infections, resistance to sulphonamides developed very 
quickly. At the beginning, the cure rate was 95% with less than 10% of the isolated 
strains showing resistance in vitro [5,49]. Within a few years, the cure rate failed by 
80% and most of the isolated strains had become resistant to sulphonamides [5]. 
From 1945 onwards, penicillin became the drug of first choice in the treatment of 
gonorrhea. Publications about development of resistance and failure of therapy were 
scarce in the first 10 years of use. in this form of therapy, probenecide should also 
be given simultaneously. The number of isolated strains that required more than 0.05 
units of penicillin per ml for growth inhibition rose from 0.67% in 1955 to 65% in 
1968 [50]. In 1945, 100,000 units of procaine penicillin were sufficient to effectively 
treat gonorrhea. In 1972, treatment required to 4.8 million units. Uptil then there has 
been talk of chromosomally mediated resistance. 
N. gonorrhoeae strains which require 1 J.i-g/ml or more for their growth inhibition 
and which do not produce ~-lactamase are referred to as chromosomally mediated 
resistant N. gonorrhoeae (CMRNG) strains. Chromosomally mediated resistant N. 
gonorrhoeae strains arise from random selection. Mutation induced resistance is 
generally relative and not absolute and is expressed as a reduced cell permeability 
for drugs such as tetracycline, penicillin, sulphonamides and erythromycin or via 
alterations in the bacterial ribosomes as described for aminoglycosides. Chromoso-
mally mediated resistance to various antibiotics occurs frequently in strains isolated 
from the rectum of homosexual men. These isolates harbour the MTR -gene more 
frequently, which results in reducing permeability for toxic faecal lipids and 
antibiotics [51]. Until 1977, there was a decline in the susceptibility for penicillin 
and tetracycline. In March 1976, the frrst penicillinase-producing N. gonorrhoeae 
(PPNG) strain was isolated in the United States. The mechanism of resistance was 
completely different and was caused by a new plasmid with genes coding for a 
~-lactamase (an enzyme) which is able to split-open the B-lactam ring of penicillin. 
This circular extra-chromosomal DNA was derived from Haemophilus species. N. 
gonorrhoeae has a TEM-1 type ~-lactamase which is typical for many Gram-
negative enteric bacilli. In 1983, N. gonorrhoeae strains with chromosomal mediated 
resistance to penicillin and tetracycline were isolated. These strains required 2-4 
Jlg/ml penicillin and 4 Jlg/ml tetracycline for in vitro growth inhibition. In 1985, 
plasmid mediated high-level tetracycline resistant N. gonorrhoeae strains (TRNG) 
which required more than 16 Jlg/ml tetracycline for growth inhibition were isolated 
in the United States. This plasmid originated from a tetracycline-resistant strepto-
coccus determinant (TetM). In 1985, in The Netherlands twelve N. gonorrhoeae 
strains of type TRNG/PPNG were isolated [52]. 
Spectinomycin resistance is indicated when more than 64 Jlg/ml is required for 
growth inhibition. It is a single-step chromosomally mediated resistance in which the 
susceptibility of N. gonorrhoeae ribosomes for spectinomycin is altered. This 
alteration is highly drug-specific. 
Spectinomycin-resistant gonococci have been isolated mainly in south east Asia 
and in England. In South Korea, it was observed that 8% of the N. gonorrhoeae 
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strains isolated from the american soldiers in 1985 were resistant to spectinomycin. 
Ten cases were reported in the United States between 1985 and 1986 [53]. The high 
incidence of spectinomycin resistance among american soldiers in South Korea was 
attributed to its widescale use of the drug [54]. Resistance to spectinomycin ltas not 
yet been observed in The Netherlands. 
Kanamycin-resistant N. gonorrhoeae strains have not yet been reported, but in 
vitro susceptibility is declining [55]. 
Trimethoprim-sulphamethoxazole (TMP-SXM) is a snitable alternative to treat 
gonorrhea. Nine tablets of TMP-SMX given for 3 days cured 96% of the men with 
uncomplicated gonorrhea [57]. Four tablets of TMP-SMX given for 2 days cured 
97% of the men with gonococcal urethtitis. Chromosomally mediated resistance to 
trimethoprim-sulphamethoxazole has been reported in the literature. 
N. gonorrhoeae is also able to develop non-specific resistance. A single-step 
alteration which results in reduced susceptibility to many agents such as antibiotics, 
detergents and colour pigments. Such non-specific resistance involves changes in the 
cell surface resulting in reduced permeability of the outer membrane or an alteration 
in the number of peptidoglycan cross-links. The exact mechanism is not !mown. 
Thiamphenicol is also used for treating gonorrhea. In 1984, a large series of 
clinical and microbiological studies on the efficacy of thiamphenicol for the 
treatment of gonorrhea was published [56]. A single oral dose of 2.5 g thiam-
phenicol resulted in a cure rate varying from 59% to 99%. A decreased suscep-
tibility of N. gonorrhoeae for thiamphenicolltas been reported from south east Asia 
and from some parts of Africa. Thiamphenicol is unsuitable for treating rectal and 
oropharyngeal gonococcal infections. 
Disappointing results with therapy-failures in 25% of the cases were observed 
when erythromycin was used to treat gonococcal infections. In vitro, many strains 
of N. gonorrhoeae were resistant to etythromycin [59]. 
Pharmacokinetic studies and in vitro research on the flrst generation cephalo-
sporins showed that they were unsuitable for treating gonorrhea [60]. However, 
certain second generation cephalosporins were found to be suitable for treating 
gonorrhea. In vitro, the MIC 90 of cefuroxime for PPNG and non-PPNG strains was 
observed to be 1 iJ.g/ml. A cure rate of more than 96% was obtained with 
intramuscular cefuroxime at a dose of 1.0 g. Treatment of uncomplicated gonorrhea 
with cefonicid resulted in cure rates varying from 94% to 96% [61,62]. The use of 
third generation cephalosporins and quinolones in gonococcal infections is described 
in chapter 1.2.1. 
The present recommendations by WHO and CDC in Atlanta (Georgia, USA), for 
the treatment of gonococcal infections have all evolved under the influence of 
factors such as the spread of annbiotic-resistant strains (including PPNG and TRNG 
strains), the spread of strains with chromosomally mediated multi-antibiotic 
resistance, the frequent occurrence of coinfection with C. trachomatis, the 
knowledge of possible serious complications of gonococcal and chlamydial 
infections, and the Jack of reliable, rapid and payable tests for detecting C. 
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trachomatis infections. The present recommendations for therapy from CDC in 
Atlanta are as follows. A single intramuscular (im) injection of 250 mg ceftriaxone 
followed by oral (po) 100 mg doxycycline twice daily for 7 days. Alternatives are 
2.0 g spectinomycin (im), 500 mg ciprofloxacin (po ), 800 mg norfloxacin (po ), 1.0 
g cefuroxime axetil & 1.0 g probenecid (po), 1.0 g cefotaxime (im) and 500 mg 
ceftizoxime (im). All these anti-gonococcal therapies are given as a single dose and 
should be supplemented with anti-chlamydia! therapy comprising 100 mg 
doxycycline (po) twice daily for 7 days [63]. 
The epidemiology of gonococcal infections is complex. Factors that influence the 
prevalence depend on diverse demographical, sociological, clinical and biological 
variables. The clinical presentation of gonococcal infections depends on the race, 
sexe, age and sexual orientation. The study of gonococcal infections should, 
therefore, be multidisciplinary and falls within the scope and interests of social 
scientists, epidemiologists, clinicians and microbiologists. The prominent increase 
in the incidence of gonococcal infections which began in 1960 came to an abrupt 
end in the middle of the 1980s and reversed into a sharp decline [64]. The number 
of cases of gonococcal infections reported in The Netherlands in 1985 was 12451. 
This number declined steadily to 3024 reported cases in 1989. In 1990 there was an 
increase to 3669 cases. The total nnmber of reported cases since 1981 are shown in 
Figure 1. 
At the University Hospital Rotterdarn-Dijkzigt, a steady decline in the number of 
reported patients with gonococcal infections began in 1984. In 1983, there were still 
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Figure 1. Number of patients suffering from gonococcal infections in The Netherlands. 
Registrated by the medical head inspector of public health, from 1981 till 1991. 
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Figure 2. Number of patients suffering from gonococcal (GO), Chlamydia trachomatis (Ct) infections 
and the number of men suffering from non·gonococcal urethritis (NGU) in the period 1980-1991 visiting 
the out-patient clinic for sexually transmitted diseases at the University Hospital Rotterdam-Dijkzigt. 
1539 reported cases which declined to 1367 cases in 1984 and declined further to 
287 reported cases in 1989 (Figure 2). This reduction in the total number of reported 
patients with gonococcal infection was not only observed in The Netherlands but 
also in other industrial nations and could have been probably due to the changes in 
sexual behavior coinciding with the arrival of Human Immunodeficiency Virus 
(HIV) infections [65]. 
In The Netherlands, data compiled in 1988 within the framework of surveillance 
for penicillinase-producing gonococcal strains indicated that despite a significant 
reduction in the incidence of gonococcal infections, the prevalence of PPNG strains 
was increasing. Fourteen percent of the gonococcal strains isolated were observed 
to produce penicillinase. In 1986, 9.6% and in 1987 11.4% of the isolated 
gonococcal strains produced penicillinase. From a total of 416 penicillinase-
producing gonococcal strains, 9.1% were also observed to possess, in addition, a 
plasmid mediated resistance to tetracycline [66]. Figure 3 gives a review of these 
data in the period 1986-1990. 
A detailed mapping of which particular N. gonorrhoeae strains are in circulation 
at any given moment is not only important for epidemiologists but also essential for 
clinical drug research. To date, gonococcal strains are typed using auxotyping, 
serotyping, lectin agglutination as well as susceptibility testing to a variety of 
antibiotics. 
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Figure 3. Prevalence of penicillinase-producing N. gonorrhoeae (PPNG) and penicillinase-producing 
tetracycline resistant N. gonorrhoeae (PPNG{TRNG) in The Netherlands, from 1986-1990. 
1.2.1. New drugs in the treatment of gonococcal infections 
An antibiotic comes into consideration for treating gonococcal infections provided 
it has a low MIC, achieves a high peak serum level and has a long half-life time. 
There are no exact conditions or criteria which these variables must satisfy. In order 
to obtain insight into the relationship between the MIC value, the serum con-
centration and the duration for which this concentration is maintained for a given 
antibiotic, Jaffe et a! [69], conducted investigations in volunteers who were infected 
with a gonococcal strain of known MIC for penicillin. The results showed that if the 
peak level of penicillin in the serum was 3 to 4 times as high as MIC of the 
infecting strain and if this level was maintained for 7 to 10 hours, then this could 
serve as an indicator for the effectiveness of the therapy. Whether this also applies 
to other antibiotics in not kno\VIl. 
According to the WHO, a drug for treating gonococcal infections must satisfy the 
following criteria: it should have a cure rate of 100%, should be usable in both men 
and women irrespective of age, should be administrable in a single dose, should be 
non-toxic, should have no cross-reaction with other antibiotics, should be non-
allergenic, should invite no resistance formation, should not be the sole drug 
effective against other serious infections, should be effective against at the same 
time aquired syphilis and C. trachomatis infections, should produce a low incidence 
of post-gonococcal urethritis and should be payable[70]. 
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The Quinolones 
The quiuolones are closely related to nalidixic acid (in use since 1962) as far as 
their structure and mode of action is concerned. Antibacterial activity of quinolones 
is mediated via the inhibition of bacterial DNA-gyrase which is essential for DNA-
transcription and for the generation of messenger RNA. Quinolones are broad 
spectrum antibiotics with a bactericidal action. In vitro studies have shown that the 
newer quinolones have much lower :MICs than nalidixic acid against N. gonor-
rhoeae. In vitro activity of various quinolones against N. gonorrhoeae are depicted 
in Table 2. The quinolones have also been tested extensively against penicillinase-
producing gonococcal strains. Taking into account their unique mode of action, it 
is not surprising that PPNG strains are highly susceptible to quinolones and that 
there is no correlation between the 'MIC values of quinolones and the production of 
j)-lactarn.ase. The quinolones are as effective against chromosomally mediated 
penicillin resistant as well as tetracycline resistant gonococcal strains. Clinical 
investigations should demonstrate whether the very promising ::MIC values except 
that of nalidixic acid would be effective in treating gonococcal infections and 
whether the mutual differences in the MIC values of quiuolones would be of clinical 
value and also be reflected in their clinical efficacy. The side-effects of quinolones 
are dose-dependent and comprise gastrointestinal disorders (3 to 5.6%), central 
nervous system disorders (0.9 to 4.4%) and allergic reactions (0.5 to 2.2%) [83]. 
An up-to-date review of clinical studies in men is given in Table 3. 
Table 2.In vitro activity of quinolones against Neisseria gonorrhoeae 
quinolone (total no. isolates/ MIC (Mg/m1) references 
no. of PPNG's) 
range 50% 90% 
difloxacin (30/3) <0.0039-0.03 72 
PD 127-391 (30/?) 0.001-0.008 0.001 0.001 71 
ciprofloxacin (1172/128) 0.0005-0.12 0.002 0.008 75 
rosoxacin (2560/515) <0.001-1.0 0.03 0.06 75 
norfloxacin (955/200) <0.0015-0.5 0.03 0.06 75 
A-56620 (30/?) 0.004-0.008 0.008 0.016 71 
fleroxacin (773/143) 0.004-1.0 0.0!5 0.03 75 
ofloxacin (601/97) 0.004-0.5 0.015 0.06 75 
lomefloxacin (342/40) 0.004-0.5 0.005-0.015 0.03-0.06 71, 76-78, 79 
pefloxacin (149/10) 0.008-0.12 0.015-0.016 0.03-0.06 71, 80, 82 
enoxacin (496/59) <0.0125-1.6 0.03 0.06 71 
nalidixic acid (60/30) 0.25-2.0 1.0 1.0 71 
sparfloxacin (250/49) 0.0063-0.0125 73 
sparfloxacin (56/7) 0.001-0.02 0.004 0.06 74 
temafloxacin (55/?) 0.001-0.12 0.008 0.03 203,250 
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Table 3. Quinolones in the treatment of uncomplicated gonorrhea in males. 
regimen (single cases cured/cases treated (% cured) references 
oral dose) 
urethra rectum pharynx 
ciprofloxacin 100 mg 71/71 (100) 84-86 
250mg 334/334 (100) 10/10 (100) 7/18 (88) 84, 86-93 
250 mg 26/26 (100) 15/16 (94) 87 
250 mg 83/83 (100) 88 
500 mg 84/84 (100) 5/5 (100) 90,91 
enoxacin 400 mg 99/100 (99) 2/2 (100) 0/3/ (0) 94,95 
400 mg/800 mg - 38/38 (100) 10/10 (100) 15 
difloxacin 200 mg 29/29 (100) 72 
fleroxacin 400 mg 97/97 (100) 3/3 (100) 96-99 
400 mg 15/15 (100) 101 
200 mg 16/16 (100) 100 
400mg 45/45 (100) 100 
temafloxacin 200 mg 31/32 (97) 203 
400 mg 40/40 (100) 203 
norfloxacin 800 mg 173/173 (100) 2/2 (100) 102, 103 
ofloxacin 100 mg 26/26 (100) 104 
200 rng 24/24 {100) 104 
400mg 211/215 (98) 19/19 (100) 8/9 (89) 105-108 
600 mg 32/34 (94) 105 
800 mg 28/29 (96) 105 
pefloxacin 800 mg 35/35 (100) 1/1 (100) 80 
800 mg 65/65 (100) 81 
rosoxacin IOOmg 5/18 (28) 109 
200 mg 15/17 (88) 109 
300 mg 40/42 (95) 2/2 (100) 109-110 
400mg 16/17 (94) 109 
Ciprofloxacin 
Excellent results were obtained at doses of 100 mg, 250 mg and 500 mg. 
Excellent results were also obtained in rectal gonorrhea. The number of patients 
with oropharyngeal gonorrhea evaluated was too small to allow any firm 
conclusions. 
Ciprofloxacin was well tolerated and side-effects were minimal and transient. 
Enoxacin 
Satisfactory results were obtained with 400 mg. In a study, enoxacin at doses of 
400 mg and 800 mg was reported to be highly effective in patients with rectal-
and or pharyngeal gonorrhea [15]. Enoxacin was well tolerated by all patients 
who have been treated to date. 
Dilloxacin 
Difloxacin at a dose of 200 mg was highly effective in treating gonococcal 
infections. To date, only patients with urethtal gonococcal infections have been 
treated. In 4 patients with C. trachomatis coinfection, chlamydia could not be 
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cultured after treatment. This drug was not investigated in further smdies since 
side-effects were observed in 65.5% of the patients who were treated. 
Fleroxacin 
Fleroxacin at a dose of 400 mg was highly effective in treating gonococcal 
infections. To date, patients with rectal gonorrhea have not been treated and 
although the number of patients suffering from oropharyngeal gonorrhea who 
were treated was too small to allow any finn conclusion, all 3 patients who were 
treated were cured. No side-effects were observed. 
Norfl.oxacin 
Norfloxacin at a dose of 800 mg was highly effective in treating gonococcal 
infections. To date, no information is available on treatment of rectal gonorrhea. 
The number of patients with oropharyngeal gonorrhea who were treated was too 
small to allow any defmite conclusion. The results in 2 patients with oropharyn-
geal gonorrhea who were treated were very promising. Side-effects were mild, 
although in one study side-effects were observed in 23.7% of the patients [102]. 
Ofloxacin 
At doses of 100 mg, 200 mg, 400 mg, 600 mg and 800 mg ofloxacin, excellent 
results were obtained. Satisfactory results were also obtained in patients with 
rectal- and pharyngeal gonorrhea who were treated with 400 mg ofloxacin. The 
drug was well tolerated. 
Pefloxacin 
All 100 patients who were treated with 800 mg pefloxacin were completely cured. 
No patients with rectal gonorrhea have yet been treated, but one patient with 
oropharyngeal gonorrhea was successfully treated. No side-effects were observed. 
Rosoxacin 
Rosoxacin at doses of 100 mg and 200 mg was not effective in treating 
gonococcal infections. At doses of 300 mg and 400 mg, rosoxacin showed lower 
cure rates of 94% and 95% respectively as compared with other antibiotics in the 
same group. On the average, side-effects were observed in 51% of the patients 
who were treated [109,110]. 
Temafloxacin 
At doses of 200 mg and 400 mg excellent results were obtained. No data are 
available obtained in patients with rectal and pharyngeal gonorrhea. Both 
treatment regimes were well tolerated. 
Conclusion 
The results of clinical investigations with these drugs correlated well with the 
results of in vitro studies except that rosoxacin scored lower in clinical studies. In 
studies in which C. rrachomatis was cultured, ouly difloxacin at the single dose 
given was effective in eliminating the infection. 
All the quinolones except difloxacin were well tolerated. The occurrence of post-
gonococcal urethritis was not different from other anti-gonococcal therapies. 
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The third generation and new oral cephalosporins 
Cefotaxime, cefoperazone, ceftriaxone, ceftazidime, cefmenoxime, cefsulodin and 
cefodizime are among those that belong to this group of antibiotics. All these 
bactericidal antibiotics have antibacterial activity similar to that of broad spectrum 
penicillins. These drugs are only snitable for parenteral administration which 
limits their use. Therefore, cephalosporins for oral use were developed. The fJtSt oral 
cephalosporins were cephalexin and cephardine. The subsequently developed 
cefaclor is ~-lactamase unstable. Cefuroxime axetil is an ester of cefuroxime 
and belongs to the second generation cephalosporins and is suitable for oral 
administration. Mter absorption ill the gastrointestinal tract, cefuroxime axetil is 
unesterified to cefuroxime. Newer drugs are ceftetrame, cefetamet, cefetamet pivoxil 
and cefJ.Xime. A review of in vitro activities of various cephalosporins against N. 
gonorrhoeae is given in Table 4. With the exception of cephalex.in and cefadroxil, 
all the others mentioned in Table 4 are highly effective against N. gonorrhoeae. 
The therapeutic effectiveness of cephalosporins already in clinical use to treat 
uncomplicated gonorrhea are depicted in Table 5. 
Cefotaxime 
Intramuscular cefotaxi.me at doses of 0.5 g and 1.0 g was highly effective in 
treating gonococcal infections. Excellent results were also obtailled in patients 
with rectal gonorrhea who were treated with 1.0 g cefotaxirne. Although, the 
number of patients with oropharyngeal gonorrhea who were treated was too small 
Table 4. In vitro activity of third generation and new oral ccphalosporines against Neisseira 
gonorrhoeae. 
compound (total no. isolates/ MIC ("g/ml) references 
no. of PPNG's) 
range 50% 90% 
cefotaxime (227/77) 0.001-0.125 0.003-0.03 0.007-0.125 112-115 
ceftazidime (207{77) 0.003-0.12 0.016-0.03 0.032-0.06 112, 114 
cefodizime (123/42) 0.004-0.25 0.004-0.05 0.016-0.25 112. 113, 116 
ceftizoxime (102/2) 0.001-0.004 0.004 117 
cefpimizole (46/1) 0.015-LO 118 
(11/2) 0.1-1.6 <0.4 <0.8 119 
ceftriaxone (107/35) <0.00 1-0.007 0.001 0.003 114 
ceftibuten (50/26) <0.002-0.12 0.008 0.03 120 
cefetamet (39/5) 0.004-1 0.015-0.12 0.25-1 115, 121 
ceftetrame (39/5) 0.004-0.25 0.008-0.03 0.12 llS, 121 
cephalexin (24/5) 0.06-16 4 121 
cefadroxil (24/5) 0.12-32 4 8 121 
cefetamet pivoxil (41/7) 0.001-0.12 0.007-0.004 0.015-0.008 122, 132 
cefuroxime axetil (124/0) 0.001-4.0 <0.03 <0.12 123 
cefixime (400/100) <0.001-0.063 0.004-0.016 <0.05 124, 126 
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Table 5. Third generation and new oral cephalosporins in the treatment of uncomplicated 
gonorrhea in ma]cs. 
cephalosporine dose Cases cured/cases treated (% cured) references 
uretlua rectum pharynx 
cefotaxime 0.5 g im 95j95 (100) 3/4 (75) 127 
1.0 g im 297/300 (99) 20/20 (100) 10/11 (91) 128 
ceftizoxime 1.0 g im 49/49 (100) 117 
cefpimizole 0.125 g im 17/24 (71) 0/1 (0) 1/2 (50) 118 
0.25 g im 20/24 (83) 118 
0.5 g im 19/21 (90) 3/3 (100) 0/1 (0) 118 
1.0 g im 22/22 (100) 1/2 (50) 0/1 (0) 118 
ceftriaxone 125 mg im 122/122 (100) 52/52 (100) 16/16 (100) 129. 130 
250 mg im 533/538 (99) 58/58 (100) 94, 129, 131 
250 mg im 81/82 (99) 88 
500 mg im 133/134 (99) 129 
cefetarnet pivoxil 0.4 gpo 10/10 (100) 132 
0.8 gpo 12/12 (100) 132 
1.2 gpo 10/10 (100) 132 
1.2 gj 
1.5 gpo 74/74 (100) 133 
cefuroxime axetil 1.0 gpo 61/64 (95) 7/9 (78) 0/1 (0) 123, 134 
1.5 gpo 106jl07 (99) 5/5 (100) 135 
cefuroxime axetil 1.0 gpo 29/30 (97) 6/6 (100) 123 
+ probenecid 1 g. 
cefixime 800 mg po 96j97 (99) 1/1 (100) 6/8 (75) 124 
800 mg po 63j63 (100) 6/6 (100) 6/7 (86) 249 
400 mg po 56/58 (97) 10/10 (100) 8/8 (100) 249 
to allow definite conclusions, treatment with 1.0 g appeared promising. Side-
effects were minimal and transient. 
Ceftizoxime 
In 1984, a small number of patients were treated with ceftizoxime with excellent 
results. Since at the beginning of the study, a majority of patients experienced 
pain at the injection-site, mepivacaine was added to the regimen. Additional side-
effects were not observed. 
Cefpimizole 
In a dose-fmding study in 1986, patients were treated with cefpintizole at doses 
of 0.125 g, 0.25 g, 0.5 g, and 1.0 g. Satisfactory results were obtained in the small 
number of patients using 1.0 g. Since the number of patients with rectal- and 
pharyngeal gonorrhea was too small, no firm conclusions concerning the 
therapeutic effectiveness could be drawn. Pain at the injection-site in 59% of the 
patients was the only observed side-effect. The investigators concluded that 
cefpimizole offered no additional advantage over the already existing anti-
gonococcal therapies. 
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Ceftria.....:one 
Excellent results were obtained at doses of 125 mg, 250 mg and 500 mg 
ceftriaxone used to treat patients with urethral, rectal and pharyngeal gonococcal 
infections. The drug was well tolerated by all patients. 
Cefelamet pivoxil 
In a dose-fmding study, a small number of patients were treated with cefetamet 
pivoxil at doses of 0.4 g, 0.8 g and 1.2 g. Excellent results were obtained. 
No patients with rectal- or pharyngeal gonorthea were treated [132]. Mild side-
effects were observed in a few patients. In an earlier study in 1988 in which a 
large number of patients with urethral gonorrhea were treated with cefetamet 
pivoxil, excellent results were obtained. The drug was well tolerated by all 
patients. 
Cefuroxime axetil 
At doses of 1.0 g and 1.5 g cefuroxime axetil, satisfactory results were obtained. 
Since only 7 of the 9 patients with rectal gonorrhea who were treated with 
cefuroxime axetil. were cured, in a subsequent study, lg probenecid was added to 
the regimen. In six patients with rectal gonorrhea, who were treated with such 
regimen, N. gonorrhoeae could not be cultured from any case after treatment. 
Treatment with 1.5 g cefuroxime axetil cured 106 of the 107 (99%) patients with 
urethral gonorrhea and 5 of the 5 ( 100%) patients with rectal gonorrhea. The drug 
was well tolerated by all patients. No comment concerning the effectiveness of 
cefuroxime axetil in patients with oropharyngeal gonorrhea can be made since no 
patients have yet been treated. 
Cefixime 
At a dose of 800 mg and 400 mg satisfactory results were obtained. The drug was 
well tolerated. 
Conclusion 
Cephalosporins both for oral and parenteral use, with the exception of cefpi-
mizole, have fulfilled the expectations. Ceftriaxone is the most effective of the 
parenteral drugs for treating urethral-, rectal- and oropharyngeal gonorrhea. 
Cefotaxime produced not only satisfactory results in the treatment of patients with 
urethral gonorthea, but also produced excellent results in the treatment of patients 
with rectal gonorrhea. No comments can be made concerning the effectiveness of 
the remaining drugs in treating rectal and pharyngeal gonorrhea because only a 
limited number of patients have been treated to date. 
The new oral cephalosporins are also effective in the treatment of urethral 
gonorrhea. To date, only a limited number of patients with rectal- and pharyngeal 
gonorrhea have been treated with these drugs to allow any fmn conclusions 
concerning their therapeutic effectiveness. 
The frequency of post-gonococcal urethritis in patients who were treated did not 
differ from that in patients who were treated with the new quinolones. At the single 
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dose that was used in the above mentioned studies, cephalosporins failed to 
effectively eliminate C. trachomatis coinfection. 
The criteria to which a drug must satisfy to be used for treating gonococcal 
infections include low MIC values, high peak serum values and a long half-life. In 
Table 6, a summary of these variables and therapeutic effectiveness is shown. 
Although quinolones and cephalosporins are highly effective in treating gonococcal 
infections, the ideal drug as proposed by the WHO still remains elusive. The 
quinolones are ineffective in treating syphilis, are contraindicated in children and in 
pregnancy due to cartilage-abnormalities observed in animals treated with 
quinolones. Given as a single dose, quinolones are also ineffective in treating C. 
trachomatis infections and in reducing post-gonococcal urethritis. At this moment 
the quinolones are too expensive for the third world. Advantages of the quinolones 
are: the oral use, no cross resistance with other antibiotics. In the future resistance 
of N. gonorrhoeae for quinolones could form a problem. 
Cephalosporins, are ineffective against C. trachomatis infections and can mask a 
coinfection with T. pallidum. The development of cephalosporins for oral use can 
be beneficial. There is a small chance for a cross resistance with penicillin.. 
Chromosomal mediated penicillin resistant gonococci (CMRNG) are also less 
susceptible to cephalosporins. [149] 
Table 6. Pharmacokinetics of the various drugs used in the treatment of uncomplicated gonorrhea. 
drug d<><e mean peak T 1/2 MIC90 efficiency reference; 
serum level (holll'S) (!.lgfml) (%) 
()Jgfml) 
Quinolones: 
ciprofloxacin 500 mg po 2.3 3.9 0.008 100 75. 84-93, 137 
difloxacin 200 mg po 2.2 26 0.01 100 72 
enoxacin 400 mg po 3.7 6.2 0.06 90-100 15, 71, 94, 95. 138 
fleroxacin 400 mg po 5.0 10 0.03 100 75, 96-99, 140 
norfloxacin 800 mg po 2.4 4 0.06 100 75, 102, 103. 136 
oflox.acin 400 mg po 4.4 6 0.06 94-100 75, 104-108, 139 
pefloxacin 400 mg po 5.8 11 0.03 100 71. so. 82, 141 
rosox.acin 300 mg po 6.4 5 0.06 96-100 75, 109, 110 
sparflox.acin 200 mg po 0.95 15 0.0125 111 
temaflox.acin 400 mg po 5.3 7.6 0.03 100 203.204 
Cephalosporines: 
cefotaxime I gim 20.5 1.3 0.016 99-100 60, 112-115, 127, 128 
cefodizime 1 g im 59 3.8 0.008 ll2, 113, ll6, 142 
ceftizomixe 1 g im 40.9 1.9 0.004 100 ll7, 143 
cefpimizole 1 gim 38.6 2 0.8 100 118, 144 
ceftriaxone 500 mg im 49 7.5 0.003 98-100 94, 114. 129-131. 145 
ceftetrame 1.2 gpo 7.25 1.5 0.12 ll5, 121, 146 
cefetame: pivoxil 1.5 gpo 7.4 3 O.Dl5 100 122. 132, 133, 147 
cefuroxime axetil ester 1 gpo 6.3 1.2 <0.12 95-99 123. 134, 135, 148 
cefixime 400 mg po 3.85 3.5 <0.05 99 124. 125, 249 
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1.3. NON-GONOCOCCAL URETHRITIS 
Non-gonococcal urethritis (NGU) is at the present, the most frequently occurring 
sexually transrnined disease (STD) in the industrialized countries including United 
Kingdom, United States and The Netherlands [150]. In a study of 1492 patients for 
genital pathogens, N. gonorrhoeae was cultured from 9.6% of the men, C. 
trachomatis was cultured from 29.6% of the men and U. urealyticum was cultured 
from 302% of the men [151]. The causes of NGU are summarized in Table l. In 
35-60% of the patients, C. trachomatis was not only the cause but was also 
responsible for the subsequent complications. There seems to be a world-wide 
Chlamydia epidemic [152]. In 25-50% of the cases of NGU, one gropes in the dark 
as far as the cause is concerned [153]. 
Genus Chlamydia can be divided into 3 sub-groups, Chlamydia trachomatis, 
Chlamydia psittaci and Taiwan acute respiratory (TWAR)Chlamydiae [154]. They 
are obligate inttacellularly dividing bacteria. To date 15 serotypes of Chlamydia 
trachomatis have been identified using immunofluorescence techniques. Serotypes 
A, B, Ba and C are associated with trachoma. Serotypes D, E, F, G, H, I, J and K 
occur in oculogenital infections. Serotypes L 1, L2 and L3 occur in lympho-
granuloma venereum. An investigation to the serotypes of isolates from urethra and 
cervix of patients who attended the STD clinic of the University Hospital 
Rotterdam-Dijkzigt showed that types D, E, F, H and K occurred most frequently 
[155]. In men, C. trachomatis causes NGU, post-gonococcal urethritis, epididymitis, 
proctitis, conjunctivitis and Reiter's syndrome [156]. 
There are no clear clinical differences between gonococcal and non-gonococcal 
urethritis, though generally, the symptoms of non-gonococcal urethritis are less 
fulminant. The incubation period of a chlamydia! urethritis is 21 to 45 days [157]. 
Chlamydia! urethritis occurs more frequently in male younger than 20 years of age 
[158]. Asymptomatic carriage of C. trachomatis in sexually active adolescent boys 
in some studies was observed to be between 8 and 9% [11,159]. The peak of post-
gonococcal urethritis is between 2 and 3 weeks after a successfully treated 
gonococcal urethritis. In 80 to 100% of the cases, C. trachomatis was the cause. The 
occurrence of N. gonorrhoeae and C. trachomatis coinfections is estimated at 10 to 
50% [160]. 
Irrespective of the aetiology, about 30% of the patients with NGU either have 
persisting complaints or relaps within 6 weeks after treatment [150]. The aetiology 
of persistent or recurrent non-gonococcal urethritis remains unknown. Most cases 
begin with a typical NGU, without a positive culture. This form of NGU responds 
poorly to antibiotics generally prescribed for NGU. Infection with antibiotic-resistant 
microbes such as tetracycline-resistant U. urealyticum strains. microbes which cannot 
be cultured using the routine methods, a reinfection of the urethra from a peripheral 
focus such as the prostate or a non-infectious cause probably of allergic origin have 
all been mentioned as possible causes for this type of urethritis. 
In addition, poor patient-compliance, a reduced absorption of the drug or a 
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reinfection via an Inadequately treated partner may play a pcssible role ln patients 
with C. trachomatis or U. urealyticum infections. In particular, patients with 
complaints of prostatitis, respond pcorly to therapy [150]. In a study on the 
prevalence of M. genitalium in patients with urethritis, it was observed that this 
microbe played no aetiological role, however this microbe may play a role in 
persistent and recurrent urethritis [161]. To date, the role of U. urealyticum ln 
causing NGU is not clear. U. urealyticum was isolated from 20% of the patients 
younger than 50 years without complaints of urethritis attending a non-venereo-
logical out-patient clinic. From between 7 to 10% of the patients older than 50 
years, U. urealyticum was isolated [162]. In sexually Inactive men, the presence of 
nreaplasmas 1n the urethra could be demonstrated for a year or longer, but 
disappeared later. 
B. ureolyricus, an anaerobic microbe is observed more frequently in patients with 
NGU than ln patients without urethritis. In a double bllnd placebo controlled study 
with metronidazole in patients with C. trachomatis negative urethritis, it was 
observed that 7 of the 9 patients with a positive anaerobe culture responded to 
metronidazole therapy, whereas, only I of the 4 patients ln the placebo group 
responded. Six of the 26 men with a negative anaerobe culture responded to 
metronidazole [163]. B. ureolyticus probably plays a minor role ln the aetiology of 
NGU [163,164]. 
Trichomonas vaginalis and herpes simplex virns are responsible ln less than 5% 
of the NGU cases. 
Clinically, patients with epididymitis caused by C. trachomatis present with 
unilateral testicular paln, swelllng and fever. In a study of 51 men with acute 
epididymitis, it was observed that ln 19 of the 42 (46%) heterosexual men and ln 
none of the 9 homosexual men, C. trachomaris was the cause [25]. 
E. coli was the cause ln 67% of the homosexual men and ln none of the 
heterosexual men. In addition, bacteriuria occurred frequently in homosexual men. 
There are only case reports on U. urealyticum as the cause of acute epididymitis 
[165]. 
The incidence of C. trachomatis infections is lower in homosexual men than in 
heterosexual men. 
Proctitis in homosexual men, besides many other causes can also be caused by C. 
trachomatis. In a study in homosexual men with proctitis, it was shown that C. 
trachomatis and N. gonorrhoeae could be cultured from respectively 10% and 31% 
of the patients [166]. C. trachomatis play no role 1n prostatitis [167,168]. 
Aseptic arthritis occurs ln approximately 3% of the cases as complication of STD 
and Intestinal infections with certain bacteria [169]. The term "sexually acquired 
reactive arthritis"' (SARA) should not be used here since only a proportion is caused 
via a sexually transmitted disease and stigmatization of the patients must be avoided. 
Urethritis, arthritis and conjunctivitis form the classic triad in Reiter's syndrome. 
About one third of the patients with a reactive arthritis have the classic Reiter's 
Syndrome. 
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C. trachomatis could be isolated from the urethra of one-third of the patients and 
in one-half of the patients elevated titres of lgG antibodies to C. trachomatis were 
present [170, 171]. The natural course of Reiter's syndrome is that two-thirds of the 
patients heal within 6 montha. Healing is generally quicker in patients who are 
HLA-B27 negative, in whom only a single or a few joints are affected and who have 
no extra articular lesions. In 15% of the cases, the disease follows an aggressive 
course with the destruction of affected joints [172]. Psoriasis and Reiter's syndrome 
are regarded by some as variants of the same cutaneous disease [173,174]. 
Chlamydia! conjunctivitis occurs via accidental digital transfer from the urogeuital 
region. In adults it progresses as an acute follicular conjunctivitis. The course of the 
disease is self-limiting. Permanent damage of the eye is very rare. Sometimes the 
course is chrouic [175]. 
In the 1950s, tetracyclines, erythromycin and sulphonaruid-arninocyclitol were the 
most effective therapeutic agents for treating NGU. More recent studies have shown 
that tetracyclines and erythromycin are effective against C. trachomatis and most of 
the U. urealyticum strains [176]. Sulphonaruids are effective against C. trachomatis 
but not against U. urealyticum. For years, tetracyclines and erythromycin have been 
the drugs of first choice for treating NGU. Although these drugs generally produce 
satisfactory results, they are by no means ideal. Tetracyclines have numerous side-
effects such as gastrointestinal disorders and overgrowth of candida which presents 
as vulvovaginitis in women and as balanoposthitis in men. In addition, tetracyclines 
cannot be used in pregnancy, in lactating mothers and in children. Erythromycin is 
a suitable alternative for treating above mentioned groups. Besides their gastrointes-
tinal side effects, different erythromycin preparations are unreliable because of 
bioavailability problems. 
Tetracyclines and erythromycin have the same in vitro activity of 0.06 J.lg/ml 
against C. trachomatis [176]. The MIC 90 of tetracycline against U. urealyticum is 
1 J.lg/ml and that of erythromycin is 0.5 J.lg/ml. 
A cliuical cure in 80% of the patients with NGU is the maximum obtained with 
these drugs despite a seeming elimination of C. trachomatis [177]. An explanation 
for this may be the possible polymicrobial aetiology of NGU. Other problems in 
cliuical studies that may be encountered in this field are the duration of therapy, the 
patient-compliance, recurrence or reinfection, possible ineffective treatment of the 
partner(s), the follow-up and the reduced bioavailability of tetracycline if taken with 
milk. Arya et al [178] used six different treatment schedules in order to investigate 
the dose, the length of therapy and the type of tetracycline preparation that was 
required to obtain the maximum therapeutic effectiveness in patients with NGU. The 
patients were divided into three treatment groups and were examined for 12 weeks 
after the start of the therapy. The first group of patients were treated with a single 
dose of 300 mg doxycycline. Within 2 weeks after treatment, 28 of the 45 (62%) 
patients had to be retreated due to therapy-failures. The second group of patients 
were treated with 3 different tetracycline preparations for 7 days. 
Oxytetracycline at a dose of 250 mg four times daily for 7 days cured 99 of the 
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127 (78%) patients. Triple tetracycline at a dose of 300 mg twice daily for 7 days 
cured 84 of the 120 (70%) patients. Doxycycline at a dose of 200 mg on the first 
day followed by a dose of 100 mg for 6 days cured 83 of the 113 (74%) patients. 
The third group of patients were treated for 21 days with triple tetracycline and 
oxytetracycline using the same doses that were used to treat the patients in the 
second group. Oxytetracycline treatment cured 66 of the 85 (78%) patients, whereas, 
triple tetracycline cured 61 of the 72 (85%) patients. The conclusion of this study 
was that a single 300 mg dose of doxycycline was ineffective in treating patients 
with NGU. Oxytetracycline treatment for 7 days produced the best results and cured 
78% of the patients. The therapeutic effectiveness after 21 days of therapy was not 
superior to the therapeutic effectiveness after 7 days of therapy and was, therefore, 
of little clinical value in the routine treatment of patients with NGU. In this study 
a clear association between renewed therapy and sexual contact during the 
investigation period was observed. In a study conducted by Juvakoski et al [179], 
patients with C. trachomaris positive urethritis were treated with 200 mg doxycy-
cline on day 1 and subsequently with 100 mg doxycycline for 6 days or with 1.0 g 
tetracycline chloride for 7 days. Patients were exantined 7 and 14 days after therapy. 
Fifty-five of the 62 (89%) patients who were treated with doxycycline were 
bacteriologically cured after 7 days, whereas, 45 of the 55 (82%) patients who were 
treated with tetracycline were bacteriologically cured. Five patients (8%) who were 
treated with doxycycline and 7 patients ( 13%) who were treated with tetracycline 
relapsed. When the number of leukocytes were examined in the urine sediment after 
7 days of therapy, all 62 (100%) patients who were treated with doxycycline and 53 
of 55 (96%) patients who were treated with tetracycline were cured. At 14 days after 
therapy, C. trachomatis could not be cultured either from any of the returning 54 
patients who were treated with doxycycline or from any of the returning 42 patients 
who were treated with tetracycline. Evaluation of urine sediments 14 days after 
therapy showed no abnormalities in patients who were treated with doxycycline, but 
abnormalities in the urine sediment were observed in 2 patients who were treated 
with tetracycline. 
It can be concluded that neither of the two tetracyclines at the particular doses 
used was suitable for treating C. trachomatis positive urethritis. Absence of 
abnormalities in urine sediment is no guarantee that chlamyd.ial infection is over and 
exantination later than 14 days after treatment is not meaningful. Bowie [180] 
compared the effectiveness of 1.0 g and 2.0 g tetracycline given for 7 days in 200 
men with urethritis. C. trachomatis was isolated from 40% of these patients and U. 
urealyticum was isolated from 48% of these patients. U. urealyticum was isolated 
more frequently from patients with chlamydia negative urethritis and from men with 
10 or fewer sexual partners during their life-time. Patients were examined 3, 14 and 
35 days after therapy. Therapy-failures were observed in 28 of the 76 (37%) patients 
who were treated with 250 mg tetracycline four times daily and in 22 of the 67 
(33%) patients who were treated with 500 mg tetracycline four times daily. When 
tissue culture results were taken into account, therapy-failures were observed in 13 
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of the 59 (22%) patients with chlamydia positive urethritis and in 37 of the 84 
( 44%) patients with chlamydia negative urethritis. When treatment schedule was 
taken into account, therapy-failures were observed in 5 of 29 (17%) chlamydia 
positive patients who were treated with 1.0 g tetracycline and in 8 of the 30 (27%) 
chlamydia positive patients who were treated with 2.0 g tetracycline. Therapy-
failures were observed in 17 of the 42 (40%) patients with U. urealyticum positive 
urethritis who were treated with 1.0 g tetracycline and in 9 of the 30 (30%) patients 
with U. urealyticum positive urethritis who were treated with 2.0 g tetracycline. It 
can be concluded that at both doses, tetracyclines were equally effective in treating 
patients with C. trachomatis and U. urealyticum positive urethritis. 
Therapy-failures were identical in both groups. Therapy-failures were frequenter 
in patients with chlamydia negative urethritis and in men in whom U. urealyticum 
persisted after treatment. Tjiam eta! [181] compared two different dose schedules 
of doxycycline to treat NGU. Patients were examined 1 day after treatment. The frrst 
group of patients was treated with 200 mg doxycycline on the first day followed by 
100 mg doxycyline for 6 days. The second group of patients was treated with 200 
mg doxycycline for 7 days. C. trachomatis was isolated from 40 of the 117 (34%) 
patients. In the frrst group, 51 of the 59 (87%) patients were cured and in the second 
gronp 49 of the 58 (84%) patients were cured. When the C. trachomatis culture 
results were taken into account, in the frrst group 20 of the 23 (87%) patients with 
chlamydia positive urethritis were cured and in the second group 13 of the 17 (76%) 
patients with chlamydia positive urethritis were cured. In the frrst group 31 of the 
36 (86%) patients with chlamydia negative urethritis were cured and in the second 
group 36 of the 41 (88%) patients with chlamydia negative urethritis were cured. 
Chlamydia was cultured from 3 patients who were considered clinically cured. There 
were no differences in the cure rates of c~amydia positive urethritis and chlamydia 
negative urethritis. 
Scheibel eta! [182] compared the effectiveness of tetracycline and erythromycin 
in patients with chlamydia positive urethritis. Patients were examined 1 and 7 days 
after therapy. 
Bacteriological cure was observed in 34 of the 36 (94%) patients who were 
treated with 250 mg erythromycin four thnes daily for 7 days and in 33 of the 35 
(94%) patients treated with 250 mg tetracycline four times daily for 7 days. No 
abnormalities in the urine sediments were observed after treatment in any of the 
patients. One patient who was treated with erythromycin and 3 patients who were 
treated with tetracycline still had dysuria. Both drugs were equally effective in 
treating chlamydia positive patients with NGU. 
At the present time, I 00 mg doxycycline twice daily for 7 days or 500 mg 
tetracycline four thnes daily are recommended for treating patients with NGU [63]. 
As alternative therapies, the following are recommended: erythromycin base 500 mg 
four thnes daily for 7 days, 800 mg erythromycin ethylsuccinate four thnes daily for 
7 days, 400 mg erythromycin ethylsuccinate four thnes daily for 14 days or 250 mg 
erythromycin base four times daily for 14 days. 
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In order to obtain insight into the compliance of patients with NGU who were 
treated for 3 weeks with 250 mg tetracycline four times daily, the tetracycline tablets 
were marked with phenobarbitone [183]. Patients were requested to return for 
examination after 2 weeks. Thirty-nine of the 62 (63%) patients failed to return for 
examination. Nine of the 33 (27%) evaluable patients had not complied with the 
therapy schedule and was also admitted as such by these patients. The phenobar-
bitone serum levels were too low in these patients. Five patients assured having 
complied with the therapy schedule but had too low phenobarbitone serum levels. 
Only 18 patients had phenobarbitone levels which were identical to the serum levels 
in volunteers who had been treated using the same therapy schedule. In these 
patients there was no evidence that they had not taken the medication properly. Poor 
therapy compliance was the reason for therapy-failure only in 1 patient. 
No reliable data are available in The Netherlands on the correlation between the 
occurrence of NGU and C. trachomatis infections. The number of patients with 
NGU at the STD clinic of the University Hospital Rotterdam-Dijkzigt began to 
decrease after 1985. This decrease was less than that of patients with gonococcal 
infections (Figure 2). At present, the number of patients with NGU is three times as 
high as that of patients with gonorrhea. In Figure 2, a survey of the numbers of 
patients since 1980 is given. The number of C. trachomatis infections in men and 
women at the STD clinic of the University Hospital Rotterdam-Dijkzigt had 
increased from 191 positive cultures in 1983 to 357 positive cultures in 1989. This 
increase was atttibuted to an improved accessibility for culmring C. trachomatis. 
The percentage of cultures that were positive during this period remained 
approximately the same(± 10%) with the exception of 1984 during which 5.2% of 
the cultures were positive. In an investigation into the occurrence of C. trachomatis 
infections at the STD clinic of the Groenburgwal in Amsterdam, it was observed that 
14.3% of the men had a C. trachomatis infection and 11.5% of the men had 
gonorrhea. The number of C. trachomatis infections in bi- and homosexual men was 
extremely low [184]. 
A possible cause for the less prominent reduction in NGU as compared to 
gonorrhea may lie in the fact that NGU affects heterosexual men who may feel less 
at risk for infections with H1V and did not change their sexual behavior. In the 
beginning, the anti-AIDS campaign was mainly directed at the high risk groups such 
as homosexual men and intravenous drug users. Tiris campaign received a broader 
basis later on. In the United States also, the number of chlarnydial infections is twice 
as high as the number of gonococcal infections [185]. 
Until! recently, C. trachomatis has not developed resistance to tetracyclines [186]. 
A decreased in vitro susceptibility of C. trachomatis for erythromycin is suspected 
[187]. 
Jones et al [188] isolated C. trachomatis strains resistant to tetracycline from five 
patients. These isolates were also resistant to doxycycline, erythromycin, sulfa-
methoxazole and clindamycin. The clinical significance of this resistance is not 
lrn.own. Tetracycline resistance of U. urealyticurn has been known for some time and 
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defined as MIC > 64 j.lg/ml. The incidence of in vivo resistance of U. urealyticum 
to tetracycline in patients with NGU was estimated at 6 to 10% [189]. 
Investigations by Robertson et a! [190], showed that in tetracycline-resistant U. 
urealyticum strains, no plasmid was present, but a tetM sequence was detected. 
Twenty-six tetracycline-resistant strains were tested using various antibiotics. All 
strains were susceptible to rosaramycin but were resistant to 2 mgjl erythromycin. 
1.3.1. New drugs in the treatment of non-gonococcal urethritis 
At present, 200 mg doxycycline for 7 days is the drug of frrst choice for treating 
patients with NGU. As second choice, 500 mg tetracycline four times daily for 7 
days is recommended. Doxycycline is chosen in the hope of increasing patient-
compliance and reducing the risk of side-effects. Similar to tetracycline, the 
bioavailability of doxycycline is also reduced when taken with milk [191]. 
Erythromycin is the drug of first choice in patients who are allergic to tetra-
cycline, in pregnancy and in children. The development of new therapies for NGU 
is necessary taking into account the therapeutic effectiveness of the currently used 
drugs, the polymicrobial aetiology of NGU and the large number of patients who fail 
to return for examination after therapy. A single oral gift which would also cure the 
gonococcal and luetic coinfections would be preferable. The recently developed new 
qninolones and new macroiides are currently being tested. Kojima et al [192] 
reported the first successful one minute therapy in men with chlamydia positive 
urethritis. All 98 patients with C. trachomatis positive urethritis who were treated 
orally with a single dose of sulphamethopyrazine (a long working sulphonamide) 
were cured when examined 14 and 21-35 days after treatment. No side-effects were 
observed. 
The quinolones 
A review of the in vitro activity of quinolones against C. trachomatis is given in 
Table 7. The in vitro activity of nalidixic acid, rosoxacin and norfloxacin is poor. 
Ofloxacin, sparfloxacin and tema:floxacin closely followed by ciprofloxacin are the 
most active against C. trachomatis. Good in vitro activity against C. trachomatis 
was also observed with fleroxacin, lomefloxacin and pefloxacin. 
A review of the in vitro activity of quinolones against U. urealyticum is given in 
Table 8. Nalidixic acid and cinoxacin have very high MIC values against U. 
urealyticum and are, therefore, unsuitable as therapeutics. The remaining quinolones 
shown in Table 8 do not differ significantly from each other with respect to their 
activities against U. urealyticum. These in vitro studies form a good base for clinical 
evaluations. 
A review of clinical investigations in patients with NGU is given in Table 9. The 
diagnosis of NGU is made provided that more than 10 leukocytes are observed in 
the urine sediment using a magnification of 250 x and the Gram-stained preparation 
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Table 7. In vitro activity of quinoloncs against Chlamydia trachomatis 
Quinolone (no. of isolates) MIC (~g/ml) references 
range 50% 90% 
ciprofloxacin (18) !.0-4.0 194 
(73) 0.39-5.0 0.39-5.0 1.0-5.0 75 
(45) 0.78-1.56 193 
(11) !.0 197 
enoxacin (21) 2.0-40.0 2.0-40.0 8.0-40.0 75 
fleroxacin (2) 4.0-2.0 3.0 205 
(6) !.5-2.5 75 
(18) 8.0 194 
lomefloxacin (10) 2.0 79 
(18) 1.0-4.0 194 
(45) !.56-3.15 193 
(11) 2.0 197 
nalidixic acid (3) >64->1600 >64->1600 >64->1600 75 
norfloxacin (30) 4.0-50.0 4.0-50.0 8.0-50.0 75 
(45) 12.5-25.0 193 
(29) 16.0 194 
ofloxacin (23) 0.5-8.0 0.5- !.0 0.5-4.0 75 
(18) !.0-4.0 194 
(27) <1.0 195 
(45) 0.39-0.78 193 
pefloxacin (18) 2.0-8.0 196 
rosoxacin (76) >1.0-80.0 > 1.0-10.0 5.0-80.0 75 
sparl'loxacin (12) 0.25 0.5 198 
(50) 0.03-0.06 199 
(9) 0.063 73 
(6) 0.62-0.125 198 
temafloxacin (50) 0.125-0.25 199 
(49) 0.03-0.5 0.125 0.25 202 
(18) 0.5-!.0 196 
shows no Gram-negative intracellular diplococci. The term "bacteriological cure" 
implies that after treatment, the causing microbes can no longer be cultured. The 
term "clinical cure" is understood by some investigators as resolution of complaints 
and by others as resolution of both complaints and abnormalities in the urine 
sediment. 
Ofloxacin 
Eleven patients with C. trachomatis positive urethritis and 19 patients with C. 
trachomatis negative urethritis were treated with 200 mg ofloxacin twice daily for 
7 days [210]. The follow up was done one day and 14 days after therapy. All 
cultures were negative. The results showed that 20 of the 30 (67%) patients bad 
no symptoms or complaints of urethritis after treatment. Mild side-effects not 
lasting more than 3 days were observed in 13% of the patients. At this dose, 
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Table 8. In vitro activity of quinoloncs against Ureaplasma urealyticum. 
Quinolone (no. of isolates) MIC ("g/ml) references 
r.mge 50% 90% 
rosoxacin (58) 0.5->62.0 4.0 8.0 75 
(51) 2.0-4.0 4.0 4.0 206 
norfloxacin (49) 4.0-64.0 16.0 32.0 75 
(31) 4.0-16.0 8.0 16.0 206 
(19) 4.0-64.0 32.0 64.0 208 
ciprofloxacin (68) 0.5->64.0 2.0 8.0 75 
(56) 2.0-64.0 8.0 16.0 206 
(20) 2.0-16.0 4.0 8.0 208 
enoxacin (49) 4.0-64.0 32.0 64.0 75 
(32) 4.0-16.0 8.0 16.0 206 
ofloxacin (49) 1.0-16.0 4.0 8.0 75 
(58) 0.5-4.0 2.0 2.0 206 
difloxacin (29) 0.5-2.0 1.0 2.0 206 
(28) 2.0->256.0 8.0 16.0 209 
pefloxacin (40) 1.0-4.0 2.0 4.0 206 
fleroxacin (50) 2.0-8.0 4.0 4.0 206 
lomefloxacin (32) 0.5-8.0 4.0 4.0 206 
(104) 4.0-16.0 8.0 8.0 207 
cinoxacin (49) >128.0 >128.0 206 
nalidixic acid (60) 64.0 256.0 206 
temafloxacin (28) 2.0->256.0 4.0 32.0 209 
sparfloxacin (34) 0.5 1.0 198 
(50) 0.5 200 
of!oxacin is highly effective in eradicating C. trachomatis. In patients with NGU, 
the therapeutic effectiveness of of!oxacin is similar to that of tetracycline. In an 
investigation of 17 patients with chlamydia positive urethritis, who were treated 
with 200 mg of!oxacin twice daily for 7 days, it was observed that after treatment, 
chlamydia could not be culmred in any case [211]. Patients were examined 7 and 
14 days after treatment. Side-effects were minimal. Whether these patients were 
also clinically cured was not explicitly reported in this smdy. 
A randomized comparison study in patients with C. trachomatis positive and C. 
trachomatis negative urethritis who were treated either with 300 mg ofloxacin 
twice daily or with 100 mg doxycycline, twice daily, showed that there was no 
difference in the cure rates obtained with these two drugs. Patients were evaluated 
21 to 28 days after therapy. Minimal side-effects were observed [212]. 
In a randomized study 17 men with NGU were treated with 300 mg ofloxacin 
twice daily for 7 days or doxycycline I 00 mg twice daily for 7 days. Patients 
were examined 2 and 3 weeks after therapy. Nine of the men had positive culmres 
for C. trachomatis and all had negative culmres after therapy. Four patients with 
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Table 9. Multidose quinolone regimens in the treatment of acute non-gonococcal urethritis. 
reglln<n culture before therapy bacteriological cure clinical cure references 
(one week unless given otherwise) (%) (%) (%) 
ofloxa.cin 200 mg BID 
Ctneg 19{30 (63) 11/19 (58) 210 
Ct po< 11/30 (37) ll/ll (100) 9/11 (82) 
ofloxacin 200 mg BID 
Ct po< 17/17 (100) 17/17 (100) 211 
ofloxacin 300 mg BID 
Ctpo< 11/29 (38) 10/11 (91) 212 
Uupo< 4/29 (4) 3/4 (15) (98) 
Ct pos{Uu pos 5/29 (17) 5/5 (100) 
Ct neg/Uu neg 9/29 (31) 9/9 (100) 
ofloxacin 300 mg BID 
Ct po< 5/9 (55) 5/5 (100) 9/9 (100) 213 
Uupo< 1/3 (33) 1/3 (33) 
fleroxacin 400/800 mg 
Ct po< 19/19 (100) 19/19 (100) 
fleroxacin 400 mg 
Ctpo< 9/16 (56) 6/9 (67) 215 
Uupo< 7{16 (44) 5{7 (71) 10/16 (62) 
fleroxacin 600 mg 
Ct po< 5/18 (28) 4/5 (80) 215 
Uupo< 10/18 (12) 9/13 (69) 11/18 (61) 
fleroxacin 800 mg 
Ct po< 7/15 (47) 3[7 (43) 215 
Uupo< 8/15 (53) 6/8 (15) 14/15 (93) 
fleroxacin 600 mg 
Ct po< 27/27 (100) 25/27 (92) 216 
fleroxacin 600 mg 
Ct po< 26/26 (100) 25/26 {100) 25/26 (96) 217 
ciprofloxacin 750 mg BID 
Ct neg!Uu pos 12{71 (17) 9/12 (!5) 218 
Ct pos/Uu pos 14{71 {20) 4/14 (29) 
Ct pos/Uu neg 22{71 (31) 10/22 (46) 
Ct neg{Uu neg 23{71 (32) 14/23 (61) 
ciprofloxacin 500 mg BID 
Ct po< 14/37 (38) 3/14 (21) 3/14 (21) 219 
Uupo< 9/37 (24) 4/9 (44) 
Ct neg/Uu neg 14/37 (38) 4/14 (28) 
ciprofloxacin 1.5 g 
Ct 1'0' 94{94 (100) 88{94 (94) 84/94 (89) 220 
ciprofloxacin 750 mg BID 
Ctpo< 21/38 (55) 10/21 (48) 20/38 (53) 221 
Ctneg 17/38 (45) 
ciprotloxacin I g BID 
Ctpo< 16/41 (39) 10/16 (62) 21/41 (51) 221 
Ct neg 25/41 (61) 
rosoxacin 150 mg BID x 10 days 
Ct neg{Uu pos ll/31 (35) 3/15 (20) 2/15 (13) 222 
Ct pos/Uu pos 4/31 (13) 1/13 (8) 0/13 (0) 
Ct pos/Uu neg 9/3! (29) 
Ct neg{Uu neg 7/31 (23) 4[7 (57) 
norfloxacin 400 mg BID x 10 days 
Ct!X" 25{78 (32) 4/25 (16) 6/25 (24) 223 
Ct neg{Uu neg 27{78 (35) 17/27 (63) 15/27 (56) 
Ct neg/Uu neg 26{78 (33) 16/26 (62) 
temafloxacin 400 mg BID 
Ct po< 25/26 (96) 
Uupo< 49/85 (58) 72{77 (94) 224 
Ct "" Chlamydia trachomaris; Uu "' Ureaplasma Urealyticum; pos = positive culture; neg .. negative 
culture. 
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a positive culture for U. urealyticum were treated with doxycyline and were 
negative after therapy and out of three patients with a positive culture for U. 
urealyticum treated with ofloxacin two had positive cultures after therapy. Side 
effects were seen in 14 (44%) of the total of 32 patients treated. This study 
demonstrated that ofloxacin and doxycycline were equally effective in the 
treatment of NGU [213]. 
Fleroxacin 
In an open study, 11 patients were treated with 400 mg fleroxacin twice daily for 
7 days, 6 patients were treated with 400 mg fleroxacin once daily for 7 days and 
5 patients were treated with 800 mg fleroxacin once daily for 7 days [214]. 
Patients were examined 3 weeks after therapy. Three patients were not evaluable. 
C. rrachomatis could not be demonstrated in any of the 19 patients after therapy. 
All patients were without complaints and no abnormalities in the urine sediments 
were observed. 
Side-effects were observed in 7 patients. 
Although the number of patients in this study was small, excellent results were 
obtained. 
In a dose-fmding study with 400 mg, 600 mg and 800 mg fleroxacin, it was 
observed that acceptable clinical effects were obtained only with 800 mg 
fleroxacin [215]. Because of the large number of side-effects, frequently serious, 
observed in 15% of the patients who were treated with 400 mg and in 81% of the 
patients who were treated with 800 mg fleroxacin, this study was discontinued. 
In two other randomized studies with 600 mg fleroxacin good results were 
obtained [216,217]. The drug was well tolerated. 
Ciprofloxacin 
In a double-blind randomized study, patients with NGU were treated either with 
750 mg ciprofloxacin twice daily for 7 days or with 100 mg doxycycline, twice 
daily for 7 days [218]. Patients were examined 3 to 6 weeks after treatment. From 
a total of 225 patients who were treated, 56 (25%) patients were not evaluable. 
Thirty-seven of the 71 (52%) patients who were treated with ciprofloxacin were 
cured and 45 of the 74 (61 %) patients who were treated with doxycycline were 
cured. In patients with C. trachomatis infections only, ciprofloxacin was 
significantly less effective than doxycycline (46% versus 75% respectively). In 
patients with U. urealyticum infection only ciprofloxacin is more effective than 
doxycycline (69% versus 45% resp.). In patients from whom cultures were 
negative, ciprofloxacin treatment was as effective as doxycycline treatment (61% 
versus 64% respectively). Side-effects were mild and were observed in 19 of the 
83 (23%) patients who were treated with doxycycline and in 14 of the 87 ( 16%) 
patients who were treated with ciprofloxacin. In a study of patients with NGU, 
who were treated with 500 mg ciprofloxacin twice daily for 7 days, the following 
results were obtained [219]. Patients were examined 1, 2, 3, 6 and 12 days after 
treatment. C. trachomatis was cultured from 14 patients at the start of the therapy. 
Mter therapy, C. trachomatis was cultured once again from 11 patients. fu these 
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11 patients, urethritis was also still present. Ten of the 14 chlamydia negative 
patients had persistent urethritis or had a relapse. 
In a study with 1.5 g ciprofloxacin or doxycycline 100 mg daily for seven days 
in 200 patients with C. trachomatis infections (157 males and 43 females), neither 
treatment was effective enough in the treatment of uncomplicated urogenital 
infections caused by C. trachomatis [220]. Out of the 9 patients from whom U. 
urealyticum cultures were positive prior to treatment, from only 4 patients the 
cultures were negative after 2 weeks or more. This study showed that cipro-
floxacin at the dose used was ineffective in treating NGU. 
In a randontized, double blind study 178 men suffering from NGU were treated 
with 750 mg and 1000 mg ciprofloxacin twice daily for 7 days or 100 mg 
doxycycline twice daily for 7 days [221]. Patients were exantined 2 and 4 weeks 
after therapy. All the 10 patients with a positive C. trachomatis culture treated 
with doxycycline were bacteriologically cured. In 10 (48%) of the 21 patients 
with a positive C. trachomatis culture, treated with 750 mg ciprofloxacin and 10 
(62%) of the 16 patients with a positive C. trachomatis culture, treated with 1000 
mg ciprofloxacin, chlamydial infection was eradicated. 
Urethritis had resolved in 20 (53%) of the 38 men in the 750 mg ciprofloxacin 
group, in 21 (51%) of 41 men in the 1000 mg ciprofloxacin group and in 20 
(56%) of the 36 men in the doxycycline group. 
Side effects (gastrointestinal) were reported by 10 (19%) of the 52 patients treated 
with doxycycline, by 20 (35%) of the 57 patients treated with 750 mg cipro-
floxacin and by 20 (38%) of the 53 patients treated with 1000 mg ciprofloxacin. 
The conclusion of this study was that ciprofloxacin in dosages as high as 2 g 
daily is inadequate for treatment of C. trachomatis infections. 
Rosoxacin 
The effectiveness of 150 mg Rosoxacin twice daily for 10 days was compared 
with that of tetracycline in treating patients with NGU [222]. Patients were 
examined 10 and 17 days after start of therapy. After treatment with rosoxacin, 
chlamydia was cultured once again in 12 of the 13 patients, who had chlamydia 
positive cultures at the beginning of the therapy. All 10 patients with C. 
rrachomatis infections, treated with tetracycline, were bacteriologically cured. Six 
of the 31 patients, treated with rosoxacin, had no complaints or any abnormalities 
in the urine sediment indicative of urethritis. Eighteen of the 31 patients, treated 
with tetracycline, were clinically cured. After therapy, U. urealyticum was isolated 
from 12 of the 15 (80%) patients, treated with rosoxacin and from 3 of the 18 
(17%) patients, treated with tetracycline. Rosoxacin was ineffective in treating 
patients with NGU. 
N orfloxacin 
Twenty-five patients with NGU and positive chlamydia cultures were treated with 
400 mg norfloxacin twice daily for 7 days [223]. Patients were examined 7, 14, 
28 and 42 days after treatment. At 7 days after therapy, 21 of the 25 patients still 
had positive chlamydia cultures. At later examinations, two more patients had 
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chlamydia positive cultures once again. Norfloxacin was ineffective in treating 
patients with NGU. 
Temafloxacin 
In a randomized study 189 patients with NGU or non-gonococcal cervicitis were 
treated with 400 mg temafloxacin twice daily for 7 days, or 100 mg doxycycline 
twice daily for 7 days [224]. Patients were examined twice during the 28 days 
post-therapy. A bacteriological cure rate for C. trachomatis was observed in 25 
of the 26 chlamydia positive patients in both groups. The clinical cure was 93.5% 
in the temafloxacin group and 86% in the doxycycline group. Both drugs were 
generally well tolerated. 
Conclusion 
Quinolones are unsuitable for treating NGU, if NGU is considered as a whole, 
without any distinction of the causative agents isolated. Ofloxacin can be used 
successfully if only chlamydia-positive patients are considered. Quinolones shonld 
be used with reservations for treating patients with NGU since, in The Netherlands, 
there are only a few centers, which possess the necessary expertise in routinely 
cnlturing C. trachomatis. An alternative policy would be to treat patients, with 
complaints of urethritis, only after the results of tissue cultures are known and only 
then contemplate treating chlamydia-positive patients with ofloxacin. 
The Macrolides 
Macrolides are still important agents for treating infectious diseases 40 years after 
their introduction. The recent development of new macrolides has rekindled interest 
in this group of antibiotics. These new macrolides have better activity against Gram-
negative and Gram-positive bacteria. They achieve high tissue and intracellular peak 
levels in contrast to aminoglycosides and ~-lactam antibiotics. In addition, 
macrolides also have non-specific immune-stimulatory properties, such as a more 
efficient migration and phagocytosis by polymorphonucleated leukocytes. Macrolides 
inhibit the RNA dependent protein synthesis by stimulating the dissociation of 
ribosomal peptidyl tRNA. Macrolides can be both bacteriostatic and bactericidal. 
Their activity profl.les includes, among others, N. gonorrhoeae and Chlamydiae 
species. The development of resistance to macrolides is seldom plasmid mediated. 
A review of the in vitro activity of different macrolides against C. trachomatis is 
given in Table 10. In vitro effectiveness of azithromycin and roxithromycin against 
C. trachomatis is comparable to those of erythromycin and tetracycline. In vitro 
effectiveness of claritbromycin against C. trachomatis was lower as those of 
erythromycin and tetracycline. 
A review of the in vitro activity of different new macrolides against U. 
urealyticum is given in Table 11. In vitro, roxithromycin was as effective as 
josamycin against U. urealyticum, but more effective than erythromycin. Five 
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Table 10. In vitro activity of new macrolides against Chlamydia traehomatis. 
Macrolide (no. of isolates) MIC ("g/ml) references 
range 50% 90% 
azithromycin (4) 026-1.02 225 
(10) 0.064-0.25 226 
(6) O.Q75 0.111 227 
clarithromycin (?) <0.002-0.008 0.004 0.008 228 
roxithromycin (10) 0.03-0.125 230 
(3) 0.8 231 
Table 11. In vitro activity of new macrolides against Ureaplasma urealyticum. 
Macrolide (no. of isolates) MIC ("g/m1) references 
nmge 50% 90% 
roxithromycin (100) 0.1-2.0 0.5 232 
clarithromycin (28) 0.004-256.0 0.5 256.0 209 
(104) 0.05-0.5 0.2 0.2 207 
A-63075 (28) 0.5-256.0 16.0 256.0 209 
azithromycin (30) 0.125-0.5 0.25 0.5 247 
(4) 0.26-1.02 248 
(65) 1.0-4.0 2.0 4.0 207 
erythromycin-resistant U. urealyticum strains were also resistant to clarithromycin 
and A-63075 [209]. The remaining U. urealyticum strains were susceptible to 
claritbromycin. A-63075 showed higher MICs against U. urealyticum. 
Clinical ttia!s are necessary to determine the efficacy of these macrolides in 
patients with NGU. A review of the clinical ttia!s conducted with these new 
macrolides is given in Table 12. 
Satisfactory results were obtained in patients with NGU who were treated with 
400 mg erythromycin acistrate (EA) thrice daily for 10 days [233]. Patients were 
examined 4 to 10 days after treatment. There was a 100% bacteriological cure in 16 
patients with chlamydia positive cultures. Side-effects were observed in 50% of the 
patients and 2 patients had to discontinue the therapy due to side-effects. Same 
results as those obtained with EA were also obtained with 500 mg erythromycin 
stearate (ES) thrice daily for 10 days [233]. Side-effects were observed in 52% of 
the patients. 
Roxithromycin 
No difference in the effectiveness was observed in a study in which 300 mg 
roxithromycin once daily for 7 days was compared with 500 mg erythromycin 
twice daily for 7 days [234]. Patients were examined 1 and 21 days after therapy. 
Bacteriological cures were observed in 55 of the 75 (73%) patients with 
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Table 12. New macrolides in the treatment of acute non~gonococcal urethritis. 
regimen culture before ther.apy bacteriological cure clinical cure references 
(%) (%) (%) 
erythromycin acist:rate 400 mg 
TID X 10 days 
0!=. 16/48 (33} 16/16 (100) ll/16 (69) 233 
Ct pos. 32/48 (67) 25/32 (78) 
erythromycin stearate 500 mg 
TID X 10 days 
Ct pos. 21/50 (42) 20/21 (95) 12/21 (57) 233 
Ct neg. 29/50 (58) 25/29 (86) 
roxithromycin 300 mg x 7 days 
Ct pos. 75{75 (100) 55(75 (73) 63{75 (84) 234 
roxithromycin 150 mg 
BID x 10 days 
Ctpos. 94/143 (66) 93/94 (99) 235 
Uu pos. 40/143 (28) 40j40 (100) 
roxithromycin ISO mg 
BID x 10 days 
Ct pos. 75/94 89/94 (93) 235 
Uu pos. 33/94 
roxithromycin 450 mg x 10 days 
Ct pos. 68/96 92/96 (96) m 
Uu pos. 41/96 
roxithromycin 300 mg x 10 days 
Ct pos. 29/48 (60) 28/29 (96) 236 
Uu pos. 4/48 (8) 4/4 (100) 45/48 (94) 
Ct neg/U u pos. 15/48 (32) 
roxithromycin 300 mg x 7 days 
Ct neg. 43/43 (100) 38/43 (88) 237 
roxithromycin 150 mg 
BID x 10 days 
Cte= 51/60 (85) 43f47 (91) 43/47 (91) 238 
Ct neg. 9/60 (15) 
azithromycim 500 rng + 
250 rng x 2 days 
Ctpos. 25/30 (83) 22/25 (88) 239 
Uu pos. 5/30 (17) 5/5 (100) 
azithrornycin 500 mg + 
250 mg x 2 days 
Ctpos. 18(18 (100) 15/15 (100) 14/15 (93) 240 
azithromycin 1 g 
Ctpos. 17/17 (100) 17(17 (100) 17/17 (100) 240 
azithrornycin 1 g 
Ctpos. 44(58 (76) 43(44 (98) 239 
Uu pos. 14/58 (24) 11(14 (78) 
azithromycin 1 g 
Ctpos. 42/96 (44) 42(42 (100) 96(96 (100) 241 
Ct neg. 54(96 (56) 
Ct - Chlamydia trachomatis; Uu = Ureaplasma urealyticum; pos = positive culture; neg ~ negative 
culture. 
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chlamydia pcsitive cultures, who were treated with roxithromycin and in 50 of the 
71 (70%) similar patients treated with erythromycin. 
Side-effects were observed in 15% of the patients in both groups, but there was 
no termination of therapy due to side-effects. Lassus et a! [235] treated a total of 
637 patients with !50 mg roxithromycin twice daily. Clinical cure was observed 
in 91% of the patients. Bacteriological cure was observed in 90% of the patients. 
A higher dose did not improve the cure rates. Side-effects were observed in 3.5% 
of the patients. 
No differences in the effectiveness were observed in a comparative study with 
300 mg roxithromycin once daily for 10 days and 200 mg doxycycline once daily 
for 10 days [236]. The overall cure rates were 94% for roxithromycin and 89% 
for doxycycline. In the group of patients with chlamydia! infections, treatment 
with roxithromycin produced bacteriological cure in 96% of the patients, whereas, 
bacteriological cure was observed in 95% of patients with chlamydia! infections, 
who were treated with doxycycline. Side-effects were observed in 6.5% of the 
patients, who were treated with roxithromycin and in 7% of the patients, who 
were treated with doxycycline. 
In a randomized study, 87 men with a C. trachomatis negative NGU were treated 
with 300 mg roxithromycin once daily for seven days or 500 mg erythromycin 
twice a day for seven days [237]. In the roxithromycin group the clinical efficacy 
rate was 88% on day 8 and between 78% and 84% on day 21. Side effects were 
mainly gastrointestinal and occurred in 15% of the patients treated with 
roxithromycin. There was no difference with the erythromycin group. 
In a study with roxithromycin !50 mg twice daily good results were obtained. No 
side effects were observed [238]. 
Azithromycin 
Twenty-two of the 25 (88%) patients with C. trachomatis positive urethritis and 
5 of the 5 patients with U. urealyticum positive urethritis, who were treated with 
500 mg azithromycin on the frrst day and 250 mg on the second and third day 
were cured [239]. Fourty-three of the 44 (98%) C. trachomatis positive patients 
and 11 of the 14 (78%) U. urealyticum positive patients who were treated with 
a single oral dose of 1.0 g azithromycin were cured [239]. The drug was well 
tolerated. Lassus observed that 32 of the 32 C. trachomatis positive patients, who 
were treated with either of the dose schedules were bacteriologically and clinically 
cured [240]. 
In a study with 1.0 g azithromycin in a single oral dose all patients were cured. 
Side-effects were mild [241]. 
Conclusion 
Of the new m.acrolides, roxithromycin is as effective as erythromycin. Azitbro-
mycin is very effective in a single oral dose in treating C. trachomatis urethritis. 
Futher studies with azitbromycin in treating patients with chlamydia negative 
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Table 13. Pharmacokinetics of the various drugs, used in the treatment of non-gonococcal 
urethritis. 
drugs do>e mean peak TI/2 MIC90 efficiency references 
(mg) serum level (hours) {j.igfml) (%) 
(J.rg/ml) 
Ct Uu 
Quinolones: 
ofloxaein 400 5.64 7.4 0.5-4 2-8 58-100 75, 139, 193, 194, 206.210-213 
fleroxacin 400/800 5.0 10.0 2-8 4 61-100 75, 140, 194, 205, 206, 215-217 
ciprofloxacin 500{750 2.3 3.9 1-5 8-16 21-94 75, 137, 193, 197, 206, 208, 
218-221 
rosoxacin 250 6.4 5.0 5-80 4-8 0-57 75, 109, 206. 222 
norfloxacin 400 2.4 4.0 8-50 16-64 24-62 75, 136, 193, 194, 206, 208, 223 
temafloxacin 400 5.3 7.6 0.25 32 94-96 202.204 
Macrolides: 
erythromycin 
acistrate 400 2.23 3.0 2 2 69-100 233, 243, 244 
erythromycin 
stearate 500 0.93 3.0 2 2 57-95 233. 244, 245 
roxithromycin 300 12.0 8.0 0.5 I 73-99 232, 234, 235, 236-238, 242 
azithromycin 500/1000 0.37 7.0 0.111 0.5 93-100 227, 239, 240, 241, 246. 247 
clarithromycin 400 2.1 4.7 0.008 256 209, 228,246 
Ct = Chlamydia trachomatis; Uu ~ Ureaplasma Urealyticum 
urethritis and patients with chronic recurrent NGU are necessary to establish its 
efficacy. No clinical studies with clarithromycin in treating patients with NGU are 
done till now. The MIC values of clarithromycin for C. trachomatis are promising. 
In Table 13 a summary of the pharmacokinetics and therapeutic effectiveness is 
shown of the various quinolones and macrolides, used in the treatment of NGU. 
1.4. OBJECTIVES OF THE STUDY 
The main aim of the studies, reported in this thesis was: 
- to investigate the clinical efficacy and benefit of new drugs. 
Drugs demonstrating satisfactory in vitro effectiveness against microorganisms 
that cause gonorrhea and those which play a role in the development of non-
gonococcal urethritis were evaluated. 
Since coinfections with N. gonorrhoeae and C. trachomatis occur rather 
frequently, it is essential to search for antibiotics that are effective in eradicating 
both these microbes. 
- to look for the so called '"one minute treatment·. 
The fact that patients with sexually transmitted diseases are inclined to default 
treatment and often fail to return for examination after completing treatment, a 
short and simple treatment schedule is necessary. 
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- to monitor the clinical effectiveness of the currently used and newly developed 
antibiotics. 
- to monitor the increasing number of multiple drug resistant N. gonorrhoeae and 
C. trachomatis strains. 
- to obtain detailed insight into the origin of microbes causing sexually transmitted 
nrethritis and coinfections. 
- to up-to-date systematic review of in vitro and in vivo studies of gonococcal and 
non-gonococcal infections. 
This provides an excellent opportunity to assess the difficulties faced in their 
effective treatment. 
- to gain insight into the therapeutic effectiveness of new antibiotics from different 
classes and with different modes of administration. 
The investigations described in this thesis can be divided into two parts. In the 
first part, the clinical efficacies of enoxacin (a new qninolone), cefodizime (a third 
generation parenteral cephalosporin) and ceftetrame (a new oral cephalosporin) were 
assessed in patients with gonococcal urethritis. In the second part, the therapeutic 
effectiveness of ciprofloxacin (a new quinolone) and roxithromycin (a new 
macrolide) were assessed in patients with NGU. 
Susceptibilities of N. gonorrhoeae and C. trachomatis to different antibiotics were 
also assessed. 
N. gonorrhoeae and C. rrachomatis strains that were isolated from patients before 
and after treatment were also tested for possible resistance formation to the 
particular antibiotic used for treatment. These strains were also typed wherever 
possible. Side-effects and laboratory abnormalities caused by these trial drugs were 
also strictly monitored and critically evaluated. 
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SUMMARY 
In a double-blind randomized study, 155 male patients with uncomplicated 
urethral gonorrhea were given 200 mg (one capsule with 200 mg and one capsule 
with placebo; n ~ 77) or 400 mg (two capsules with 200 mg; n ~ 78) of enoxacin 
orally. The cure rates in the 200- and 400-mg treatment groups were 90 and 92%, 
respectively. The enoxac:in MIC for the isolated Neisseria gonorrhoeae strains 
ranged from 0.015 to 0.12 J.lg/ml. Postgonocccal urethritis was diagnosed in 29 
(42%) patients in the 200-mg treatment group and 19 (26%) patients in the 400-mg 
treatment group. Side effects (nausea, headache, and vomiting) occurred in 2 (3%) 
of the 77 patients in the 200-mg treatment group and in 3 (4%) of the 78 patients 
in the 400-mg treatment group. 
INTRODUCTION 
The increasing resistance of Neisseria gonorrhoeae to penicillins and tetracycline 
calls for new therapeutic agents. The 4-quinolone group has yielded some deriva-
tives that are active against N. gonorrhoeae and can be given orally. Cure rates of 
up to 100% have been reported in previous studies with ciprofloxacin in the treat-
ment of uncomplicated urogenital gonorrhea in males (12) and with enoxacin in the 
treatment of uncomplicated urogential gonorrhea in females (4,13). In vitro studies 
have shown that enoxacin, one of the new quinolone agents, is effective against N. 
gonorrhoeae with MICs of 0.03 to 0.25 J.lg/ml (8). Our double-blind randomized 
study involved clinical evaluation of the treatment of uncomplicated urethral 
gonorrhea in males with a single oral dose of either 200 or 400 mg of enoxacin. 
MATERIALS AND METHODS 
Patient population 
All patients were men attending the outpatient clinic for sexually transmitted 
diseases at the University Hospital Rotterdam-Dijkzigt. Patients who were under 18, 
had disseminated gonococcal infections, had solitary rectal or pharyngeal gonococcal 
infections, had syphilis, liver, or kidney diseases, had allergies to quinolones, and 
were recently treated with enoxacin or on theophylline medication were excluded. 
This was a double-blind study. 
A randomization list ensured that patients received a single oral dose of either 400 
mg of enoxacin in two 200-mg capsules or 200 mg of enoxacin in one 200-mg 
capsule and one placebo capsule. The capsules were taken with water under the 
supervision of a nurse. The patients were advised to abstain from sexual contacts 
throughout the follow-up period. 
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All subjects gave oral informed consent before they were enrolled, and the study 
was approved by the committee for the protection of human subjects at the 
University Hospital Rotterdarn-Dijkzigt. 
Venereological study 
A standard history was taken, and all patients underwent the following tests before 
and after therapy. Gram stains were made of the discharge, and samples for 
Chlamydia trachomatis and N. gonorrhoeae cultures were taken from the urethra. 
N. gonorrhoeae culture samples were taken from the pharynx (and from the rectum 
in homosexual men), and the sediment of 10 to 15 rul of the first-voided urine was 
collected. Blood was drawn for Venereal Disease Research Laboratory (VDRL), 
fluorescent treponema! antibody (FTA-ABS), and THPA tests (ouly before therapy) 
and general hematology, liver and kidney function determinations. Therapy was 
started if Gramnegative diplococci were found in the Gram stain or if N. gonor-
rhoeae was isolated from the culture. 
The effect of therapy was evaluated 7 to 14 days after patients began to receive 
medication. Postgonococcal urethritis was diagnosed if, at follow up, more than 10 
leukocytes per field were seen in the sediment of the first voided urine at a 
magnification of 250 x and the Gram stain contained no intracellular Gram-negative 
diplococci. At follow-up, all patients were asked about side effects and whether 
dysuria or discharge was still present. 
N. gonorrhoeae cultures 
For N. gonorrhoeae cultures, samples were taken with a carbon-impregnated 
cotton swab and, after tranport in Stuart medium, transferred within 6 h to a 
selective medium which consisted of GC agar base (Oxoid Ltd., Londen, England) 
supplemented with 2% hemoglobin (Oxoid Ltd.) and 1% JsoVitaleX (BEL 
Microbiology Systems, Cockeysville, Md). 
MJCs of enoxacin, tetracycline, penicillin, ampicillin and cefuroxime for the N. 
gonorrhoeae strains were determined by an agar dilution technique on gonococcal 
agar base (11) with twofold serial antibiotic dilutions between 4 and 0.004 J.lg/rul 
and a bacterial inoculum of 104 CFUfspot. All N. gonorrhoeae strains were tested 
for beta-lactamase production using the chromogenic cephalosporin (nitrocephin) test 
(5). 
Susceptibility to spectinomycin was tested by the disk diffusion method. 
Auxotyping of the N. gonorrhoeae strains was performed at the National Institute 
of Public Health and Environmental Hygiene (1). Pairs showing similarity before 
and after therapy were sent to the Centers for Disease Control for lectin aggluti-
nation (9) and serotyping (3) tests as described previously. 
Chapter 2 55 
C. trachomatis cultures 
For C. trachomatis cultures, samples were taken by inserting white-cotton-tipped 
metal swabs deep into the urethra, rotating them, and suspending them in buffer 
contailling 0.2 M sucrose and 0.02 M phosphate with 10% fetal calf serum, 25 mg 
of gentamicin per ml, and 25 U of nystatin per mi. Samples were frozen to -70°C 
within 6 h of being obtained. Chlamydiae were cultured on HeLa 229 monolayers 
washed with DEAE-dextran in 96-well microliter plates. Staining was done with 
fluorescent monoclonal antibodies (Syva Inc.), after 48 h of incubation (10). 
Subpassage was not performed. 
Statistical analysis 
Results were statistically analyzed by the two-tailed Fisher exact test. 
RESULTS 
Of the 243 patients treated, 88 (36%) could not be evaluated, 45 in the 200-mg 
and 43 in the 400-mg treatment group. Reasons included failure to report for follow-
up (47 patients), follow-up later than 2 weeks (17 patients), sexual contact during 
the study (11 patients), capsules vomited up innnediately after ingestion (I patient), 
negative N. gonorrhoeae culture at start of study (3 patients), and material not 
obtained for N. gonorrhoeae culture at follow-up (9 patients). 
Treatment with 200 mg of enoxacin 
In the 200-mg treatment group. 77 patients were available for evaluation; 69 
(90%) patients were culture negative for N. gonorrhoeae at follow-up. Of the 77 
patients with positive initial N. gonorrhoeae cultures, the strains were isolated from 
the urethra in all 77; none were isolated from the rectum or the pharynx. The 
auxotyping patterns of the N. gonorrhoeae strains obtained from six treatment 
failures were identical (Table 1). In two failures, one or both strains were no longer 
available for auxotyping. The typing patterns of pre- and posttreatment strains 
obtained from two nonassessable patients (one for sexual contant during the study 
and one for follow-up later than 2 weeks) showed similarity in auxo-and serotyping. 
One pall- showed a similar and one pair a different lectin agglutination pattern (Table 
1). Five (6%) of the 77 N. gonorrhoeae strains isolated produced penicillinase; the 
cure rate for this group of patients was I 00%. Postgonococcal urethritis (PGU) was 
diagnosed in 29 (42%) of the 69 patients negative for N. gonorrhoeae at follow-up. 
C. trachomatis was isolated from the urethra in 8 (28%) of the 29 patients; only 3 
of them still had complaints. Samples from 20 patients (69%) were C. trachomatis 
negative, and ouly 5 of these patients still had complaints. In one symptomatic case, 
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no C. trachomatis culture was obtained. In four cases, C. trachomatis was isolated 
in the absence of urinary sediment changes. One (1 %) patient complained of nausea 
and one (1%) of headache and nausea. 
Treatment with 400 mg of enoxacin 
In the 400-mg treatment group. 78 patients were available for evaluation; 72 
(92%) patients were culture negative for N. gonorrhoeae at follow-up. Of the 78 
patients with positive N. gonorrhoeae cultures, the strains were isolated from the 
urethra in 78, the rectum in 2, and the pharynx in 0. 
The auxotyping patterns of the N. gonorrhoeae strains from the two treatment 
failures were identical (Table 1). In four failures, one or both strains were no longer 
available for auxotyping. The typing patterus of pre- and posttreatment strains 
obtained from two nonassessable patients (one for follow-up later than 2 weeks and 
one for capsule vomited immediately after ingestion) showed similarity in auxo- and 
serotyping. One pair showed a similar and one pair a different lectin agglutination 
pattern (Table 1). Two strains isolated from two patients after therapy had enoxacin 
MICs of 1 and 2 J.!g/ml. The pretreatment strain of the first patient was no longer 
available forMIC determination. The pretreatment strain of the latter patient showed 
a MIC of 0.03 f!g/ml (Table 1). 
Table 1. :MIC's of enoxacin for N. gonon-h<Jeae strains isolated before and after therapy with 
cnoxacin and their typing patterns. 
Patient group and Pretreatment strains Posttreatment strains 
enoxacin dose 
(mg) MIC Auxotype" Serovar Lectin MIC Auxotype0 Serovar Lectin 
(~g/ml) group (~g/ml) group 
Assessable 
200 0.03 NR IB-3 6 0.03 NR IB-3 6 
0.06 ho- IB-5 7 0.06 ho- IB-5 7 
0.03 Pro- lB-4 7 0.03 Pro- IB-4 7 
0.06 Pro- lB-4 7 0.06 Pro- IB-4 7 
0.06 NRPhe IB-6 7 0.06 NRPhe IB-6 7 
0.03 Pro- lB-4 6 0.06 Pro- IB-4 6 
400 0.03 Amac- IB-3 6 0.03 Arnac- IB-3 6 
0.03 Amac- IB-2 7 2 Amac- IB-2 7 
Nonassessable 
200 0.03 NRPhe !B-6 7 0.03 NRPhe IB-6 7 
0.06 Amac- NT' 12 0.06 Amac- NT 6 
400 0.03 NR IB-6 6 0.06 NR IB-6 6 
0.03 NRPhe IB-6 12 0.03 NRPhe IB-6 7 
''NR Phe, not requiring and inhibited by Phenylalanine; Pro-, proline requiring; Amac-, amino acid 
mixture requiring (1); NR no requirement. 
m, Not typable. 
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None of the strains produced penicillinase. Two patients also had a positive rectal 
gonococcal culture. The follow-up cultures were negative for both patients. 
PGU was diagnosed in 19 (26%) of the 72 patients negative for N. gonorrhoeae 
at follow-up. C. trachomatis was isolated from the urethra in 9 (47%) of the !9 
patients; only 2 of these patients still had complaints, whereas 10 (53%) samples 
from asymtomatic patients were C. trachomatis negative. In five cases, C. 
rrachomatis was isolated in the absence of urinary sediment changes. Two (3%) 
patients complained of nausea, and one (1%) vomited a few minutes after ingestion 
of the medication. 
C. trachomatis cultures 
Before therapy, C. rrachomatis was isolated from 17 (11 %) of the 155 patients 
and after therapy from 26 (17%). 
Abnonnal laboratory findings 
The following abnormal laboratory fmdings were obtained for the 200-mg 
treatment group: enlarged platelets in two (3%) patients, a slightly increased serum 
glutamic oxalacetic transaminase value in two (3%), slight anisocytosis in two (3%), 
and a few macrocytes in one (1 %). The only abnormal fmding for the 400-mg 
treatment group was a slightly increased serum glutamic pyruvic transaminase value 
in one (1%) patient. 
Antimicrobial susceptibility and typing patterns 
Eleven (5%) of the 239 N. gonorrhoeae strains isolated produced penicillinase. 
The MICs of enoxacin ranged from 0.004 to 0.12 J.lg/rnl. The enoxacin MIC for 90% 
of isolates was 0.06 J.lg/rnl (Table 2). One N. gonorrhoeae strain showed an increase 
in the MIC from 0.03 to 2 J.lg/rnl after treatment with 400 mg of enoxacin. 
Table 2. In vitro susceptibility of N. gonorrhoeae strains isolated before treatment with enoxacin. 
MIC ("glml)' 
Antibiotic Range 50% 
Enoxacinb 0.015- 0.12 0.03 
Penicillinc O.QJS - 4 0.25 
Ampicillin 0.03 - 4 0.25 
Cefuroximeb 0.008 - 2 0.03 
Tetracyclineb 0.06 -4 0.25 
a50% and 90%. MIC for 50 and 90% of isolates, respectively. 
h-rested against all strains, including six penicillinase-producing strains (n = 134). 
CJ'ested against non-penicillinase-producing strains only (n ~ 128). 
90% 
0.06 
0.5 
0.12 
0.5 
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The lectin agglutination patterns and serotyping of each of the eight pre- and post-
treatment pairs of isolates obtained from assessable patients were identical (Table 1). 
DISCUSSION 
A study of 12 healthy control volunteers (16) demonstrated peak plasma levels 
of 1.2 flg/ml after a single dose of 200 mg and 2.1 flg/ml after 400 mg of enoxacin. 
The half-life of enoxacin is ca. 5 h. In view of the good results of our previous pilot 
study with enoxacin (4), the above-mentioned data, and low MICs of enoxacin for 
N. gonorrhoeae, we decided to investigate this quinolone in a large group of patients 
suffering from uncomplicated gonorrhea. 
The cure rate found in this study, 90% in the 200-mg treatment group, and 92% 
in the 400-mg treatment group, was lower than that in our previous study of 
enoxacin with indentical doses in the treatment of uncomplicated female urogenital 
gonorrhea (13). The cure rates in the latter study were 98.7% in the 200-mg 
treatment group and 100% in the 400-mg treatment group. Although the MICs of 
enoxacin for penicillinase-producing and non-penicillinase-producing N. gonorrhoeae 
strains were low (0.3 to 0.12 flg/ml) and agreed with those determined in previous 
studies (2,4,8) the cure rates in both groups of treated males were lower than 
expected from other studies with quinolones (4,12,13). 
Pre- and posttreatment isolates were available from six treatment failures in the 
200-mg group and two failures in the 400-mg group. Auxotyping, serotyping, and 
lectin agglutination patterns were the same for each pair of N. gonorrhoeae strains 
obtained before and after therapy. This suggests either failure of therapy or 
reinfection with the same strain. In six therapy failures auxotyping was impossible, 
and no conclusions about whether the strains were the same before and after therapy 
could be drawn. 
The fact that in two nonassessable patients the pre- and posttreatment pairs of 
strains showed the same auxo- and serotyping and lectin agglutination patterns 
underscored the importance of additional typing methods. 
The MICs of enoxacin for one N. gonorrhoeae strain rose from 0.03 flg/ml before 
therapy to 2 flg/ml after therapy with 400 mg of enoxacin. Van Klingeren et al. (14) 
demonstrated that the sensitivity in vitro of N. gonorrhoeae strains to quinolones 
may show a 10-fold to 100-fold decrease compared with the parent strain at a 
frequency of l in I 08 to I 09 These fmdings indicate that resistance to quinolones 
can develop in vivo. 
Enoxacin in a single oral dose is not effective against C. trachomatis; this is in 
accordance with the high MICs of enoxacin against C. trachomatis (MIC for 90% 
of isolates, 16 flg/ml) and data reported for other antibiotics given in a single dose 
(6,7,15). This probably explains the PGU in the 42% of the 200-mg treatment group 
and 26% of the 400-mg treatment group. Like Oriel et a!. (7), we found a larger 
number of positive C. trachomatis cultures after therapy than before. 
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The low percentage of positive C. rrachomatis cultures (28 to 47%) for patients 
suffering from PGU is probably due to the short follow-up period. It is possible that 
some patients may have persistent urethral leukocytosis due to gonorrhea alone. 
Also, enoxacin may cause temporary suppression of C. trachomatis. Of the PGU 
patients, 31% in the 200-mg treatment group and 10% in the 400-mg treatment 
group still had complaints. These low percentages are probably also due to the short 
follow-up period. The peak incidence of symptomatic PGU occurs 2 to 3 weeks after 
treatment. 
The differences in cure of gonococcal infections between the 200-mg treatment 
group and the 400-mg treatment group were not statistically significant (P > 0.05). 
The differences in PGU rate were not statistically significant either (P > 0.05). The 
side effects observed (headache and nausea) were mild and transient. Abnormal 
laboratory fmdings occurred more often in the 200-mg treatment group, than in the 
400-mg treatment group demonstrating that there was no dose-dependent relation 
with the medication given. 
Our conclusion is that enoxacin is an effective drug in the treatment of 
uncomplicated male urethral gonorrhea, although the cure rate in this study was 
lower than that in previous studies of female patients and previous studies with other 
quinolones (13). 
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SUMMARY 
Uncomplicated urogenital and concomitant oropharyngeal gonorrhea in 424 male 
and female patients was treated in a randomized comparative study with 0.5 g of 
cefodizime (89 men and 54 women), l g of cefodizime (87 men and 52 women), or 
l g of cefotaxime (86 men and 56 women). The cure rates were 100% for men and 
women in the group given 0.5 g of cefodizime, 100% for men and women in the 
group given 1 g of cefodizime, and 99% for men and 100% for women in the group 
given 1 g of cefotaxime. The MICs of cefodizime and cefotaxime for the isolate of 
Neisseria gonorrhoeae ranged from 0.004 to 0.06 flg/ml. Chlamydia rrachomatis 
was isolated before treatment in 15% and after treatment in 13% of all patients. Side 
effects, such as nausea, diarrhea, abdominal p~ genital candidiasis, and paiD at the 
site of injection, developed in 4% of the patients given cefodizime. Side effects, 
such as vertigo, genital candidiasis, fatigability, and diarrhea, developed in 4% of 
the patients treated with cefotaxime. In both groups of patients, the side effects were 
mild and transient. Cefodizime and cefotaxime are safe and effective agents in the 
treatment of uncomplicated urogenital gonorrhea. 
INTRODUCTION 
Previous studies (12-14) performed in our department during the past 2 years 
have shown that some 5% of Neisseria gonorrhoeae infections are caused by 
penicillinase-producing strains. The use of ~-lactamase-stable chemotherapeutics 
may aid in the reduction of treatment failures. 
Cefodizime is a new ~-lactamase-stable chemotherapeutic (8) for parenteral use. 
It has the same structure as cefotax.ime, with a 1-mercapto-1.3-thiazole chain on the 
third position of the dihydrothiazine ring. 
In vitro studies have shown that cefodizime is effective against strains of N. 
gonorrhoeae, with MICs ranging from< 0.004 to 0.016 flg/ml (4). A study of eight 
healthy volunteers (3) revealed that peak levels in serum of about 59 flg/ml were 
obtained after a single illtra-muscular dose of 1 g of cefodizime. The half-life was 
about 3.8 h. 
This report presents a clinical evaluation of the treatment of uncomplicated 
urogenital gonorrhea in men and women with 0.5 or 1 g of cedoflzime in a single 
intramuscular dose compared with a single intramuscular dose of l g of cefotaxime. 
Although the aim of this study was to evaluate the antibacterial effect of 
cefodizime against N. gonorrhoeae, we also decided to evaluate concomitant 
Chlamydia trachomatis infections and the urinary sediment, because of the 
epidentiological interest 
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MATERIALS AND METHODS 
All the patients attended the venereal diseases outpatient clinic of University 
Hospital Rotterdam-Dijkzigt. Patients excluded from this study included patients 
younger than 18; those suffering from disseminated gonococcal infections, solitary 
phatyugeal gonorrhea, and hepatic or renal diseases; patients with cephalosporin 
and/or penicillin allergy; those recently treated with antibiotics, probenecid, and/or 
immunosuppressive agents; pregnant or lactating women; and patients with 
gastrointestinal pathology. Metronidazole or tinidazole medication was accepted as 
concomitant antibiotic treatment during the study. All patients gave oral consent 
before study. 
Pre- and posttreatment cultures for N. gonorrhoeae and C. trachomatis were done, 
and tests were performed as follows. For men, Gram stain of discharge, urethral C. 
trachomatis culture, and urethral and tonsillar N. gonorrhoeae cultures were done. 
Rectal cultures were obtained from homosexual men. The urinaty sediment was 
tested for the presence of leukocytes in the frrst 10 to 15 mi. For women, urethral 
and cervical Gram stain, urethral, cervical, rectal, and tonsillar N. gonorrhoeae 
cultures; and cervical C. trachomatis cultures were done. 
Treatment was given on the basis of a Gram stain, positive N. gonorrhoeae 
culture, or enzyme-linked immnnosorbent assay (l) positive for N. gonorrhoeae. 
Women who had negative Gram stains but were exposed toN. gonorrhoeae through 
sexual contact were also treated. 
By using a randomization list, patients were given a single intramuscular injection 
of 0.5 g of cefodizime, 1 g of cefodizime, or 1 g of cefotaxime. 
The effect of therapy was evaluated 2 to 7 days after the patients began to receive 
medication. At follow-up visits, explicit questions were asked about side effects, 
dysuria, discharge, and abstinence from sexnal contact. The trial protocol was 
approved by the medical ethics conmtittee of the University Hospital Rotterdam-
Dijkzigt. 
Before and after treatment, blood was drawn for Venereal Disease Research 
Laboratory, fluorescent treponema! antibody-abs, and TPHA tests (only before 
therapy); general hematology; and liver and lddney function determinations. 
N. gonorrhoeae cultures 
Specimens for N. gonorrhoeae culture were taken from the urethra, cervix, tonsil, 
and rectum as described above with a carbon-impregnated swab stick; transported 
in Stuart medium; and transferred within 6 h to a selective medium consisting of GC 
agar base (Oxoid Ltd.) supplemented with 2% hemoglobin (Oxoid) and 1% 
lsoVitaleX (BBL Microbiology Systems). 
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Phenotypic characterization 
The MICs of cefodizime, cefotaxime, ceftriaxone, tetracycline, and penicillin for 
the gonococcal strains were determined by using a standard agar dilution method 
(11) with twofold dilutions between 4 and 0.004 mglliter. All gonococcal strains 
were tested for ~-lactamase production by using the chromogenic cephalosporin 
(Nitrocepbin) test (6). 
Susceptibility to specrinomycin was tested by the disk dlffusion method. 
Auxotyping of the gonococcal strains was done by the National Institute of Public 
Health and Environmental Hygiene (2). Pre- and posttreatment gonococcal strains 
with the same auxotypes were sent to the Centers for Disease Control, Atlanta, Ga., 
for examination by lectin agglutination (7) and serologic typing (5) as decribed 
previously. 
C. trachomatis cultures 
Specimens for C. trachomatis culture were taken by using a metal swab stick with 
a white cotton swab inserted deep into the urethra or cervix and rotated. The 
specimens were suspended in 0.02 M phosphate buffer containing 0.20 M sucrose 
with 10% fetal calf serum, 25 ug of gentamicin per ml, and 25 U of nystatin per 
liter. The samples were frozen at -70°C. The culture was made on HeLa 229 
monolayers prerinsed with DEAE-dextran in 96-well nticrodilution plates. 
Fluorescent staining was accomplished with a monoclonal antibody reagent (Syva 
Inc.) after 48 h (9) without subpassage. 
Statistical analysis 
Statistical analysis was performed by using Fisher's exact test (two tailed). 
RESULTS 
Treatment with 0.5 g of cefodizime 
Of 108 male patients treated with 05 g of cefodizime, 19 (18%) proved to be 
nonassessable (Table 1). Results of N. gonorrhoeae cultures of the assessable 
patients according to the site of isolation are shown in Table 2. In all 89 patients 
(100%), the gonococcal cultures became negative after antibiotic treatment. One 
patient developed candidiasis of the glans penis. Three patients (3%) showed 
transient slightly increased serum glutamic oxalacetic and pyruvic transaminase 
activities. 
Of the 67 female patients treated with 0.5 g of cefodizime, 13 (19%) were found 
to be nonassessable (Table !). 
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Table 1. Assessability of patients treated with various antibiotics. 
Characteristic No. (%) of patients 
0.5 g of cefodizime 1 g of cefodizime 1 g of cefotaxime 
Male Female Male Female Male Female 
(n - 108) (n - 67) (n- 103) (n- 66) (n - 108) (n - 72) 
Assessable 89(82) 54(81) 87(84) 52(79) 86(80) 56(78) 
Nonassessable 19(18) 13(19) 16{16) 14(21) 22(20) 16{22) 
No follow-up 17(89) 5(38) 14(88) 8(57) 16{73) 4(25) 
No laboratory confirmation of 
gonoccal infection 2{11) 5(38) 2(12) 5(36) 5(23) 12{75) 
Sexual contact and positive N. 
gonorrhoeae culture 0 2(16) 0 1{7) 1(4) 0 
No N. gonorrhoeae culture at 
follow-up 0 1(8) 0 0 0 0 
Table 2. Assessable patients with positive culture of N. gMorrhoeae by culture site. 
Site No {%) of patients 
0.5 g of cefodizime 1 g of cefodizime 1 g of cefotaxime 
Male Female Male Female Male Female 
(n - 89) (n - 52) (n- 87) (n - 52) (n - 86) (n - 56) 
Urethra 89(100) 41(79) 87{100) 12(23) 86(100) 43(77) 
Throat 0 3(6) 0 0 0 2(4) 
Rectum 0 20(38) 2(2} 17{33) 0 17{30) 
Cervix 11(12) 48(92) 6{7) 44(85) 9(10) 49(88) 
PPNGa 1{2) 1{2) 4(7) 
"Penicillinase-producing N. gonorrhoeae strains 
For 2 of the 54 assessable patients, no .N.. gonorrhoeae cultures had been made; 
the diagnosis in these patients was made on the basis of a positive enzyme-linked 
immunosorbent assay (Gonozyme) (I) and a positive Gram stain. Both patients had 
negative N. gonorrhoeae cultures after therapy. Results of N. gonorrhoeae cultures 
of the assessable patients according to the site of isolation are shown in Table 2. 
The 52 female patients (100%) with positive gonococcal cultures became negative. 
The estimated cure rate in this group of patients was 100%. 
No laboratory (hematological and liver and kidney function) changes were found. 
One patient complained of nausea, and one reported nausea, diarrhea, and abdominal 
pain. 
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Treatment with 1 g of cefodizime 
Of the 103 male patients treated with l g of cefodizime, 16 (16%) were found to 
be nonassessable (Table 1). Results of N. gonorrhoeae cultures of the assessable 
patients are shown in Table 2. In all 87 patients (100%), the gonococcal cultures had 
become negative after treatment. One patient (l%) complained of nausea, two (2%) 
complained of diarrhea, and one (l %) complained of pain at the injection site. No 
laboratory (hematological and liver and kidney function) changes were found. 
Of the 66 female patients given l g of•cefodizime, 14 (21 %) proved to be 
nonassessable (Table !). Results of N. gonorrhoeae cultures of the assessable 
patients are shown in Table 2. In all 52 female patients (100%), the gonococcal 
cultures had become negative after treatment. One patient (2%) complained of 
abdominal pain, one (2%) complained of diarrhea, one (2%) complained of nausea; 
one patient (2%) developed genital candidiasis, and one (2%) showed a slightly 
increased lactate dehydrogenase value. 
Treatment with 1 g of cefotaxime 
Of 108 male patients treated with l g of cefotaxime, 22 (20%) proved to be 
nonassessable (Table 1). Results of N. gonorrhoeae cultures of the assessable 
patients are shown in Table 2. In 85 male patients (99%), the gonococcal culture had 
become negative. One patient again had a positive urethral N. gonorrhoeae culture 
at follow-up. He denied having had any sexual contact. Auxotypings (proline 
requiring) of the gonococcal strain before and after treatment were identical, as were 
the lectin agglutination patterns (7) and the serovar (!A-4). One patient (I%) 
complained of vertigo, and one (I%) developed candidiasis of the glans penis. No 
abnormal laboratory (hematological and liver and kidney function) fmdings were 
obtained. 
Of 72 female patients treated with I g of cefotaxime, 16 (22%) were non-
assessable (Table !). Results of N. gonorrhoeae cultures of the assessable patients 
are shown in Table 2. In ail 56 female patients (100%), the gonococcal cultures had 
become negative. One patient (2%) complained offatigability, one (2%) complained 
of diarrhea, and one (2%) developed vaginal candidiasis. No abnormal laboratory 
fmdings were obtained. 
C. trachomatis cultures 
C. trachomatis was isolated before treatment from 63 (15%) of the total of 4!8 
patients and after treatment from 51 (13%) of the total of 403 patients (Table 3); 29 
patients had persistent C. trachomatis infections at follow-up, and !8 patients had 
positive C. trachomatis cultures at follow-up with a negative culture at the first visit. 
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Table 3. Results of C. trachomatis cultures of assessable patients before and after treatment. 
Drug and dose No patients with isolatesjtotal 
(g) Male Female 
Before After Before After 
Cefodizime 
0.5 7/88' 7/89 14/54 13/52b 
LO !0/85b 9/89 12/50b 8/50b 
Cefotaxime 
LO 7/851J. 9/86 13/56 5/54b 
3 No C. trachomaris culture was perfonned for one patient. 
b No C. trachomaris cultures were performed for two patients. 
Table 4. In vitro susceptibility of N. gonorrhoeae strains {n = 424)"' isolated before treatment with 
cefodizimc or ccfotaxime. 
Antibiotic Organismsb 
Cefodizime Non-PPNG 
PPNG 
All strains 
Cefotaxime Non-PPNG 
PPNG 
All strains 
Ceftriaxone Non-PPNG 
PPNG 
All strains 
Tetracycline Non-PPNG 
PPNG 
All strains 
Penicillin Non-PPNG 
PPNG 
All strains 
3 Including penicillinase-producing strains (n = 32). 
b PPNG. Penicillinase-producing N. gonorrhoeae. 
50% 
< 0.004 
< 0.004 
< 0.004 
0.004 
< 0.004 
< 0.004 
< 0.004 
< 0.004 
< 0.004 
0.5 
1 
0.5 
0.12 
>4 
0.12 
c 50% and 90%. :MJC for 50 and 90% of strains tested, respectively. 
Antimicrobial susceptibility and typing patterns 
MIC (~glmlt 
90% 
0.008 
0.016 
0.008 
0.008 
0.016 
0.008 
< 0.004 
0.008 
< 0.004 
2 
4 
2 
0.5 
>4 
1 
Of the 424 N. gonorrhoeae strains, 32 (8%) produced penicillinase. The MICs of 
cefodizime ranged from < 0.004 to 0.06 f!g/ml. The MIC of cefodizime for 90% of 
isolates tested was 0.008 f!g/ml (Table 4). The MICs of cefotaxime ranged from 
< 0.004 to 0.06 f!g/ml. The MIC of cefotaxime for 90% of isolates tested was 0.008 
f!g/ml (Table 4). The MICs of ceftriaxone ranged from 0.004 to 0.03 f!g/ml. 
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The MICs of tetracycline ranged from < 0.016 to 4 flg/ml, and the MICs of 
penicillin ranged from < 0.016 to 4 flg/ml. 
All N. gonorrhoeae strains were susceptible to spectinomycin. From three 
patients, N. gonorrhoeae was again isolated at the follow·up visit. 
Auxo- and serotypes and the lectin agglutination patterns of each of the strains 
isolated before and after treatment in the two nonassessable patients, who had sexual 
contact during the study, were likewise identical. Differences in :r-.1!Cs were not 
observed. 
DISCUSSION 
So far there have been no clinical trials with cefodizime in the treatment of 
patients with acute uncomplicated gonorrhea. ln view of the long half-life, high peak 
levels in serum, and the low MIC of cefodizime for N. gonorrhoeae, this agent is 
eminently suitable for the treatment of uncomplicated gonorrhea. The cure rate in 
the male and female patients treated with 0.5 and 1 g of cefodizime was 100%. That 
in the male patients given 1 g of cefotaxime was 99%, compared with 100% in the 
female patients. 
The low percentage of positive pharyngeal gonococcal cultnres ( 1%) precludes 
any conclusion about the effect of cefod.izime on pharyngeal gonorrhea. 
The high percentage of nonassessable female patients, for whom no laboratory 
confrrmation of gonococcal infection (Table 1) was found, was due to the fact that 
in our clinic a woman with a proved sexual contact VJith a man suffering from 
gonorrhea is treated simultaneously with her partner. The number of patients VJith 
side effects (nausea, diarrhea, abdominal pain, genital candidiasis, pain at the 
injection site, fatigability, and vertigo, always mild and transient) was smaller in the 
group treated with 0.5 g of cefodizime (2%) than in the group given 1 g of 
cefodizime (6%) and in the group treated with 1 g of cefotaxime (4%), although the 
differences were not statistically significant. 
No abnormal laboratory fmdings were obtained for the patients treated with 1 g 
of cefotaxime. Transient slightly increased serum glutamic oxalacetic and pyruvic 
transaminase activities were found in three patients given 0.5 g of cefodizime, and 
one patient given 1 g of cefodizime showed a transient slightly increased lactate 
dehydrogenase value. A relation to the medication received cannot completely be 
excluded. 
The MICs of cefodizime against penicillinase-producing and non-penicillinase-
producing N. gonorrhoeae ranged from< 0.004 to 0.06 flg/ml and corresponded with 
the values found in previous in vitro studies (4,8). 
The succes rates and toxicity profiles of cefodizime in the treatment of 
uncomplicated gonorrhea (penicillinase-produc.ing and non-penicillinase-producing 
N. gonorrhoeae) are similar to those of other broad-spectrum cephalosporins, such 
as ceftriaxone, and quinolones, such as ciprofloxacin and spectinomycin. 
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The pre- and posttherapeutic strains from one assessable patient and those from 
two nonassessable patients were identical in terms of auxo- and serotyping and lectin 
agglutination patterns; although the two patients were nonassessable because of 
sexual contact during the study, therapy failure cannot be excluded. In the case of 
the assessable patient, too, the possibility of reinfection with the same strain cannot 
be excluded. 
The brief follow-up period of 2 to 7 days precludes any conclusion about the 
occurrence of postgonococcal urethritis in the three treatment groups. The peak of 
symptomatic postgonococcal urethritis comes 2 to 3 weeks after treatment_ The low 
percentages of positive C. trachomatis cultures (10 to 11 %) should likewise be 
ascribed to the brief follow-up period. 
An agent which could cure both gonorrhea and C. trachomatis infections is 
becoming more and more desirable. Our conclusion is that cefodizime ill doses of 
0.5 and 1.0 g and cefotaxime in a dose of 1.0 g are effective, safe agents in the 
treatment of uncomplicated urogenital gonorrhea. 
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SUMMARY 
Ten male patients suffering from uncomplicated urethral gonorrhoea were treated 
orally with 1200 mg Ceftetrame (Ro 19-5248). Nine of the 10 patients were cured. 
The sensitivity of the isolated Neisseria gonorrhoeae strains to Ro 19-5247, the 
active metabolite of Ceftetrame, ranged from < 0.002 to 0.12 f!g/ml. Chlamydia 
trachomatis was isolated before and after treatment in one patient. No side effects 
were reported. Ceftetrame is an effective drug in the treatment of uncomplicated 
urogenital gonorrhoea in males. 
List of abbreviations 
MIC = Minimum Inhibitory Concentration. 
VDRL = Venereal Disease Research Laboratory-test. 
Ff A -abs = Fluorescent Treponema! Antibody Absorption. 
TPHA = Treponema Pallidum Haemagglutination Assay. 
TKA = Trichosanthes Kinlowii. 
GSI = G. simplicifolia I. 
SBA = Glycine max. 
STA = Solanum Tuberosum. 
WGA = Wheat Germ Agglutinin. 
N.R. = Non-requiring. 
INTRODUCTION 
In a previous study with cefuroxime axetil ester. an oral cephalosporin in the 
treatment of urethral and rectal gonorrhoea, a cure rate of 99.5% was observed. Side 
effects were noted in 38% of the patients1• Since then, a new generation of oral 
cephalosporins has been developped. We studied Ceftetrame (Ro 19-5248), an oral 
cephalosporin of the ester type. After absorption from the intestinal tract Ceftetrame 
is hydrolysed by esterase to an active metabolite (Ro 19-5247) which shows a very 
promising activity against Neisseria gonorrhoeae, including penicillinase-producing 
strains. The MIC for the strains previously studied ranged from < 0.004-0.25 
flg/ml2• A study of nine healthy volunteers revealed that peak serum levels of about 
7.25 mg/ml were obtained after a single oral dose of 1200 mg Ceftetrame. The half 
life-time was about 1.5 h3• This pilot study was initiated for evaluaring the efficacy 
of 1200 mg Ceftetrame in the treatment of uncomplicated acute gonococcal urethritis 
in male patients. 
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MATERIALS AND METHODS 
All patients were men attending the out-patient clinic for sexually transmitted 
diseases at the University Hospital Rotterdam-Dijkzigt. Excluded were patients under 
!8, patients with complicated gonococcal infection, patients with only rectal or 
pharyngeal gonococcal infection, patients with syphilis, liver or kidney diseases, or 
cardiovascular decompensation, patients with a hypersensitivity to cephalosporin or 
penicillin and patients treated with other antimicrobials within the preceding 2 
weeks. 
A treatment was given on the basis of a Gram stain or positive culture for 
Neisseria gonorrhoeae. 
13 Patients were treated with a single oral dose of 1200 mg Ceftetrame (12 
capsules of 100 mg). The capsules were taken with water under the supervision of 
a nurse. The patients were advised to abstain from sexual contacts during the study 
period. All subjects gave oral informed consent before they were enrolled, and the 
study was approved by the conunittee for the protection of human subjects at the 
University Hospital Rotterdam-Dijkzigt. 
Of the !3 patients treated, 3 could not be evaluated. Reasons were: 2 patients 
failed to report for follow-up and in one patient the culture for N. gonorrhoeae at 
start of the study turned out to be negative. A standard history was taken and all 
patients underwent the following tests before and 7-8 days after therapy: Gram stain 
of discharge, urethral Chlamydia trachomatis culture, N. gonorrhoeae cultures from 
urethra and tonsillae. Rectal cultures were obtained from homosexual men. The 
sediment of I 0 to !5 ml of the first urine voided at least 4 hours after the previous 
voiding was collected. Blood was drawn for VDRL, FrA-ABS, and TPHA test (only 
before therapy), and general haematology, liver and kidney function determinations. 
Nongonococcal urethritis was diagnosed if at follow-up, more than 10 leucocytes 
per field were seen in the sediment at a magnification of 250 x, and the Gram stain 
contained no intracellular Gram-negative diplococci. N. gonorrhoeae cultures were 
taken from the urethra, tonsil, and rectum as described above, using a carbon 
impregnated swab stick. They were transported in Stuart medium and inoculated 
within six hours, onto a selective medium consisting of GC agar base (Oxoid Ltd, 
London, England) and supplemented with 2% hemoglobin (Oxoid Ltd) I% Isovitalex 
(BBL Microbiology Systems, Cockeysville, USA). The MiC values of the N. 
gonorrhoeae strains for the active metabolite and cefotaxime were determined by 
the standard agar dilution method with serial twofold dilutions between 4 and 0.004 
f!g/ml. All N. gonorrhoeae strains were tested for ~-lactamase production using the 
chromogenic cephalosporin (Nitrocefm') test4 Auxotyping of the N. gonorrhoeae 
strains was performed at the National Institute of Public Health and Environmental 
Hygiene5. The pair of strains showing similarity before and after therapy were sent 
to the Centers for Disease Control, Atlanta, Georgia, USA, for lectin agglutination6 
and serotyping7. For C. trachomatis cultures, samples were taken by inserting white 
cotton-tipped metal swabs deep into the urethra, rotating and suspended in 0.02 M 
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phosphate buffer contammg 0.2 M sucrose en 10% fetal calf serum, 25 f!g/ml 
gentamicin and 25 U/ml nystatin. Samples were placed at -70°C within 6 hours. 
Chlamydia was cultured on HeLa 229 monolayers rewashed with DEAE-dextran 
in 96-well microti.ter plates. Staining was done with Microtrak fluorescent 
monoclonal antibodies (Syva Corp.) after 48 hours incubation8 Subpassage was not 
performed. 
RESULTS 
Ten patients were available for evaluation. In 9 patients cultures were negative for 
N. gonorrhoeae at follow-up. C. trachomatis was isolated before and after treatment 
in one patient. In 3 patients more than 10 leucocytes were found at follow-up, 
although C. trachomaris cultures were negative. No side effects were reported. One 
patient showed a slightly increased SGPT value and 3 patients a slightly increased 
lymphocyte count. None of the 11 N. gonorrhoeae strains produced penicillinase. 
The MIC values for the active metabolite ranged from < 0.002 to 0.12 f!g/ml. The 
MIC90 for the active metabolite was 0.03 f!g/ml. Auxotyping of the pre-and post-
treatment gonococcal strain was identical (N.R.) as was the lectin agglutination 
pattern (TKA, GS!, SBA. STA, WGA) and the serovar (l-Bl). The pre- as well as 
the posttreatment strain showed the same MIC value. 
DISCUSSION 
There have been no previous published studies on the oral treattnent of 
gonococcal urethritis with Ceftetrarne. In this study, 9 of 10 patients treated orally 
with Ceftetrame had negative gonococcal cultures at follow-up. The pre- and 
posttreatment strain from one assessable patient was identical in terms of auxo-and 
serovar typing and lectin agglutination pattern which suggests treatment failure or 
re:infection with the same strain. The results of this pilot study suggest that 
Ceftetrame is an effective drug in the treatment of uncomplicated urogenital 
gonorrhoea. 
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Enoxacin shows favourable Illl1lllilum inhibitory concentration (MIC) values, 
ranging from 0.03 to 0.12 mg/1 against Neisseria gonorrhoeae. Of 78 male patients, 
treated in our Derm.ato-venereologic out-patient department for gonococcal urethritis 
with 400 mg enoxacin in one oral dose, 92% were cured. Of the failures, one patient 
reported back with a relapse of his infection. As renewed sexual intercourse was 
denied reinfection seemed probable. Determination of the MIC values by means of 
the agar dilution technique, using a gonococcal agar base with an inoculum of 104 
CPU per spot showed a substantial increase in MIC (2.0 mgfl) of the post-treatment 
strain in comparision with the pre-treatment strain (0.03 mgfl). These results were 
conf'rrmed at the National Institute of Public Health and Enviromnental Hygiene. 
Both strains were susceptible to penicillin (MIC 0.06 mgfl) and of similar auxotype. 
Mutants of gonococci showing a ten to hundred-fold decreased susceptibility to 
quinolones as compared to the parent strains can be isolated in vitro with a 
frequency of 108-109 (Van Klingeren, Dessens-Kroon & Verheuvel, 1985). 
These fmdings indicate, that resistance has to be considered when therapy fails. 
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Recently the use of quinolone compounds was reviewed in this journal (1). The 
componnds are reported to show favourable activity in vitro against Neisseria 
gonorrhoeae (2). In 1985, however, three penicillin-sensitive (MIC < 0.03, 0.06 and 
0.6 J.lg/ml) Neisseria gonorrhoeae strains with decreased sensitivity to several 
quinolone compounds were isolated at our dermato-venereological out-patient 
department from as many patients suffering from uncomplicated urogenital 
gonococcal infection. Occurrence of this decreased sensitivity was relatively rare, 
as several hundred Neisseria gonorrhoeae strains were tested with various quinolone 
compounds. 
MIC values of ciprofloxacin, enoxacin, ofloxacin and RO 23-6240 (AM 833) 
were determined for these strains by means of the agar dilution technique, using a 
gonococcal agar base with a bacterial inoculum of I 04 CFU per spot. A decrease in 
sensitivity to these compounds was noted, MIC values being between 0.12 and 
2.0 J.lg/ml. The MIC values of ciprofloxacin, enoxacin, ofloxacin and RO 23-6240 
for the three strains were 0.12, 1.0-2.0, 0.50 and 0.50-1.0 flg/ml respectively. These 
results were reproducible. Of the compounds tested ciprofloxacin was the most 
active. The auxotype patterns of the three strains were not identical. Typical MIC 
90 values of ciprofloxacin, enoxacin, ofloxacin (I) and RO 23-6240 (2) for 
Neisseria gonorrhoeae are 0.01, 0.25, 0.05 and 0.06 flg/ml respectively. 
As with other bacterial species the existence of crossresistance to quinolones (1) 
in Neisseria gonorrhoeae must be considered when choosing a compound for 
therapy. 
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SUMMARY 
The in vitro actJ.vtt:Les of ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, 
norfloxacin, ofloxacin and pefloxacin against 10 penicillinase-producing N. 
gonorrhoeae strains (PPNG's) 10 non PPNG's, 10 non-penicillinase-producing 
penicillin-resistant chromosomally mediated N. gonorrhoeae strains (CMRNG's), 3 
N. gonorrhoeae strains with a decreased sensitivity against qninolones compounds 
and one tetracycline resistant penicillinase-producing N. gonorrhoeae (TRNG/PPNG) 
strain were evaluated in this study. The non PPNG, PPNG, CMRNG and TRNG/ 
PPNG strains showed good to excellent sensitivity to the qninolones tested. The N. 
gonorrhoeae strains with a decreased sensitivity against quinolones showed higher 
MIC (Minimum Inhibitory concentration) values. 
INTRODUCTION 
The search for new agents to treat gonococcal infections is still going on. Till now 
all of the qninolones tested in clinical trials have proved effective as single-dose 
therapy of gonorrhoeae, including the infections caused by penicillinase-producing 
isolates of Neisseria gonorrhoeae (PPNGs) [1,4]. Reports of resistance to enoxacin 
from The Netherlands and to norfloxacin from Thailand necessitates both the 
development of new therapeutic regimens as well as ongo:ing assessment of the 
effectiveness of old and new regimens. [5] There are indications for the existence 
of a cross-reacting dim.ID.ished sensitivity pattern to quinolones in Neisseria 
gonorrhoeae. [6] In this paper the activity of seven quinolone derivatives against 
different penicillinase-negative and positive N. gonorrhoeae isolates is reported. 
MATERIALS AND METHODS 
A total of 34 N. gonorrhoeae strains isolated from patients, attending the 
venereologic out-patient department of the University Hospital of Rotterdam (The 
Netherlands) were tested. Ten were penicillinase-producing (or beta-lactamase) 
(PPNG's) as detetrnined by the chromogenic cephalosporin test. [7] 
Ten were non-penicillinase producing penicillin sensitive strains (non-PPNG~s) 
(MIC 0.25 Ufml) and ten were non-penicillinase-producing penicillin-resistant 
chromosomally mediated N. gonorrhoeae strains (CMRNGs) with a MIC of 
penicillin of 1 flg/ml. Three strains had a decreased sensitivity against quinolones 
and one strain was a tetracycline-resistant penicillinase-producing N. gonorrhoeae 
(TRNGjPPNG) isolate with a MIC of tetracycline of 32 mg/1 [8]. 
The following antimicrobial agents were tested: ciprofloxacin, enoxacin, 
fleroxacin, lomefloxacin, norfloxacin, ofloxacin, pefloxacin. MICs were determined 
by using a standard agar dilution method with GC agar base (Oxoid Ltd., London, 
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England) supplemented with 2% hemoglobin (Oxoid Ltd.) and I% IsoVitalex (BBL 
Microbiology Systems, Cockeysville, Md.). Twofold dilutions of antibiotic concen-
trations, ranging from 8-0.004 mg/1, were used. The bacterial Inoculum was 104 
CFU per spot. The plates were Incubated for 18 h at 37°C In an aerobic C02 atmo-
sphere. Four bacterial strains with known MIC values were used as control strains. 
RESULTS AND DISCUSSION 
The ranges of MIC values and MIC values, required to inhibit up to 50% and 
90% (MIC 50, MIC 90) of the qulnolones against ten non-PPNG, ten PPNG and ten 
CMRNG strains are sununarized In Table 1. 
Table 1. In vitro activity of 10 non-penicillinase-producing penicillin sensitive (non-PPNG). 10 
penicillinase-producing (PPNG) and 10 non-penicillinase-producing penicillin-resistant chromo--
somaliy mediated resistant (CMRNG) N. gonorrhoeae strains. 
MIC (mg/1) 
Compound Range 50% 90% 
ciprofloxacin non-PPNG 0.004-0.008 0.004 0.008 
PPNG 0.004-0.015 0.008 0.008 
CMRNG 0.004-0.008 0.004 0.004 
total 0.004-0.15 0.004 0.008 
enoxacin non-PPNG 0.015-0.06 0.03 0.06 
PPNG 0.06 -0.12 0.06 0.06 
CMRNG 0.04 -0.12 0.06 0.12 
total 0.004-0.12 0.06 0.12 
fleroxacin non-PPNG 0.001-0.03 0.03 0.03 
PPNG 0.03 0.03 O.Q3 
CMRNG 0.001-0.06 0.06 0.06 
total 0.001-0.06 0.03 0.06 
Jomefloxacin non-PPNG O.Ql5-0.06 O.ot5 O.ot5 
PPNG O.Ql5-0.06 O.Ql5 0.015 
CMRNG 0.015-0.12 0.06 0.06 
total 0.015-0.12 O.Ql5 0.06 
norfloxacin non-PPNG 0.015-0.03 O.Ql5 0.03 
PPNG 0.015-0.03 0.015 O.Q3 
total 0.015-0.25 0.03 0.06 
ofloxacin non-PPNG 0.008-0.03 0.008 0.03 
PPNG 0.008-0.03 0.0015 0.015 
CMRNG 0.015-0.06 0.03 0.06 
total 0.008-0.06 O.Ql5 0.03 
pefloxacin non-PPNG 0.008-0.03 O.oJ5 O.QJS 
PPNG 0.015-0.06 O.Q3 0.03 
CMRNG 0.015-0.06 0.06 0.06 
toral 0.008-0.06 0.03 0.06 
Chapter 7 91 
Table 2. In vitro activity of three N. gonqrrhoeae strains with decreased sensitivity against 
quinolones (A, B, C), and one tetracycline-resistant strain (D). 
MIC (mg/1) 
Compound A B c D 
ciprofloxacin 0.12 0.12 0.12 0.004 
enoxacin 2 I 2 0.03 
fleroxacin I 0.5 0.03 
lomefloxacin 0.5 0.5 O.oJ5 
norfloxacin 0.5 2 O.oJ5 
ofloxacin 0.5 0.5 I O.oJ5 
pefloxacin 0.5 2 0.15 
The values of the three N. gonorrhoeae strains with a decreased sensitivity to 
quinolones (straill A, B, C) and the one TRNG/PPNG straill (D) are listed in 
Table 2. 
All three groups of N. gonorrhoeae strains (non-PPNG, PPNG, CMRNG) showed 
good to excellent sensitivity to the quinolone derivatives tested. No appreciable 
differences between the groups are noted. These fmdings are in agreement with 
previous reports. [9-12]. Of all quinolones tested ciprofloxacin MIC values are 
lowest. The TRNG/PPNG strain shows the same sensitivity pattern regarding the 
quinolones as other gonococci from either group. As expected the phenomenon of 
decreased sensitivity of strains to quinolone compounds resulted in higher MIC 
values than usually expected. Sofar evaluation of the clinical relevance has not been 
evaluated for fleroxacin, lomefloxacin and pefloxacin is in progress. 
Although these new drugs are promising candidates as alternative drugs for the 
single-dose treatment of gonorrhoeae, world wide use in the future remains to be 
carefully monitored. 
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SUMMARY 
One-hundred and fifty-two male patients suffering from non-gonococcal urethritis 
were treated with an oral dose of 300 mg roxithromycin daily for seven days. 
Chlamydia trachomatis was isolated from the urethra in 53 patients (35%), and 
Ureap/nsma urealyticum in 42 patients (28%). After treatment, 49 (92%) of the 53 
patients with positive Chlamydia trachomatis cultures and 34 (81 %) of the 42 
patients with positive Ureaplasma urealyticum cultures had negative cultures at 
follow-up. A clinical cure was observed in !37 patients (90%). Ten patients (7%) 
showed side effects consisting of nausea, sensation of distended abdomen, headache 
and fatigue. Seventy-eight male patients suffering from non-gonococcal urethritis 
were treated with an oral dosage of 2 x 150 mg roxithromycin daily for seven days. 
Chlamydia trachomatis was isolated from the urethra in 22 patients (28%), and 
Ureap/nsma urealyticum in 30 patients (38%). After treatment, all of the 22 patients 
with formerly positive Chlamydia trachomatis cultures and 23 (77%) of the 30 
patients with formerly positive Ureap/asma urealyticum cultures were negative at 
follow-up. A clinical cure was observed in 70 patients (90%). Three patients (4%) 
showed side effects consisting of nausea and headache. It is concluded that 
roxithromycin is a good alternative to tetr::1cycline and erythromycin in the treatment 
of non-gonococcal urethritis in males. 
INTRODUCTION 
Tetracycline and erythromycin are still drugs of choice in the treatment of male 
non-gonococcal urethritis or uncomplicated Chlamydia trachomatis infections (1). 
Scheibel (2) demonstrated that a seven-day course of erythromycin is as effective 
as a seven-day course of tetracycline in treatment of Chlamydia trachomatis 
urethritis in males. Tetracyclines may result in phototoxicity in patients, while a 
frequent side effect of erythromycin is gastric symptoms. However, erythromycin is 
safe for children and pregnant women. In view of the high prevalence of Chlamydia 
trachomaris infections, an increase of such infections in these patients might be 
expected (3). Therefore it seemed useful to evaluate the efficacy of medication with 
an alternative macrolide antibiotic, roxithromycin (RU 28965). 
This agent has the same strncture as erythromycin but has a 2-methoxy-ethoxy-
methoxy-imino group on the 9-position. In vitro studies (4) have shown that 
roxithromycin is effective against Chlamydia trachomatis and Ureaplasma 
urealyticum, with MIC values of 0.03-0.125 mcg/ml and 1.0-4 mcg/ml respectively. 
A study in 70 healthy control volunteers (5) demonstrated peak plasma levels of 
2.5 mcg/ml after a single oral dose of 50 mg roxithromycin and 16.3 mcg/ml after 
400 mg. Investigations indicated that roxithromycin was safe, well tolerated and well 
absorbed after oral administration. The half-life of roxithromycin is about 8 h. 
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The effectiveness of roxithromycin in treatment of non-gonococcal urethritis in 
males was investigated in two consecutive open trials. Patients in the first trail 
received 300 mg daily while those in the second trail were given 2 x !50 mg daily. 
Fractional doses might ensure a more constant plasma concentration, more effective 
therapy and fewer side effects. 
MATERIALS AND METHODS 
Patients Population 
A total of 296 male patients with non-gonococcal urethritis who attended the out-
patient clinic for sexually transmitted diseases of the University Hospital Rotterdam 
were enrolled for the study. One group of 186 patients received an oral dosage of 
300 mg roxithromycin daily for seven days. The other group of 110 patients 
received an oral dosage of !50 mg roxithromycin twice daily for seven days. 
Excluded from the study were patients younger than 18 years, patients who had used 
antibiotics within seven days prior to the start of therapy, patients taking theophyl-
line, anti-epileptics, ergot alkaloids, antacids or H2-blockers, patients hypersensitive 
to macrolides and patients with a history of renal disease. All subjects gave oral 
informed consent before they were enrolled, and the study was approved by the 
Committee for the Protection of Human Subjects at the University Hospital 
Rotterdam-Dijkzigt. 
Microbiogical Investigations 
All patients underwent the following investigations before and one day afrer 
completion of therapy: Gram stain of urethral discharge, and culture of urethra 
samples for Ureaplasma urealyticum, Chlamydia trachomatis and Neisseria 
gonorrhoeae; blood samples were subjected to treponema! antibody test (only before 
therapy), general haematological investigations and chemical analysis. Then the 
sediment of the frrst 10-15 ml of urine was collected when the patient had not 
voided for 4 h or longer. Non-gonococcal urethritis was diagnosed if more than ten 
leucocytes were observed in the sediment at magnification 250 times and if the 
Gram stain revealed no intracellular Gram-negative diplococci. Clinical cure was 
defined as the absence of all symptoms after therapy. A negative culture afrer 
therapy was considered evidence of bacteriological cure. At the control visit (day 8) 
all patients were asked whether they had experienced side-effects. 
Swabs for culture of Ureaplasma urealyticum were taken from the urethra with 
a wooden swab-stick and suspended in transport medium consisting of 22.5 g 
trypticase soy broth (Oxoid, UK), 200 ml inactivated horse serum, 30 ml yeast 
extract according to Hers (6), 50 ml20% urea, !2.5 ml 0.2% phenol red. 50,000 U 
penicillin G and 750 ml distilled water. Swab-stick and suspensions were frozen at 
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-70°C within 6 h. The culture was performed according to the technique of 
Shephard (7,8). Swabs for cultures of Chlamydia trachomatis were taken with a 
white cotton-tipped metal swab-stick, which was inserted deep into the urethra, 
rotated, withdrawn and suspended in 0.2 m sucrose and 0.02 M phosphate buffer 
with 10% fetal calf serum, 25 mcg/ml gentamicin and 25 U/ml nystatin. The 
samples were frozen at -70°C within 6 h. The culture was performed on HeLa 229 
monolayers pre-washed with DEAE-dexrran in 96-well titre plates. Staining was 
carried out with fluorescent monoclonal antibodies (Syva, USA) after 48 h of 
incubation (9). Subpassage was not performed. Swabs for culture of Neisseria 
gonorrhoeae were taken from the urethra with a carbon-impregnated swabstick 
which, after transport in Stuart medium, was inoculated within 6 h on a selective 
medium comprising GC agar base (Oxoid) supplemented with 2% haemoglobin 
(Oxoid) and 1% Isovitalex (BBL, USA). 
Statistical Analysis 
The results were analysed using the two-tailed Fisher's exact test. 
RESULTS 
Of the 186 patients treated with 300 mg roxithromycin daily (Table 1), 34 (18%) 
could not be evaluated due to failure to report for follow-up in 19 (56%) cases, 
sexnal contact in three (9%), no chlamydia culture at follow-up in six (17%), 
positive Neisseria gonorrhoeae culture in one (3%), improper drug intake in one 
(3%) and no Neisseria gonorrhoeae culture at the start of the study in four (12%). 
The remaining 152 patients available for evaluation included 53 (35%) in whom 
Chlamydia trachomatis and 42 (28%) in whom Ureapl.asma urealyticum was 
isolated from the urethra. After rreattnent 49 (92%) of the 53 patients with formely 
positive Chlamydia trachomatis cultures and 34 (81 %) of the 42 patients with 
Table 1. Results of therapy in relation of results of culture for Chlamydia trachomatis and 
Ureaplasma urealyticum in 230 male patients suffering from non-gonococcal urethritis before and 
after oral treatment with 1 x 300 mg or 2 x 150 mg roxithromycin daily for seven days. 
Culture results 1 x 300 mg (n-152) 2 x 150 rng (n-78) 
Chlamydia trachomatis/ Before After Resolution Before After Resolution 
Ureaplasma urealyticum treatment treatment of pyuria treatment treatment of pyuria 
Positive/positive 15 0 13 5 0 2 
Negative/positive 27 3 21 25 4 13 
Positive/negative 38 7' 33 17 0 12 
Negative/negative 72 142 56 31 74 22 
"Three positive only at follow-up. 
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formely positive Ureaplasma urealyricum cultures had negative cultures. Clinical 
cure was observed in 137 (90%) of the 152 patients. In three cases only the follow-
up Chlamydia trachomaris culture was positive. Chlamydia rrachomaris was isolated 
in six and Ureaplasma urealyticum in three clinically cured patients with a negative 
urinary sediment. Both a negative urinary sediment and clinical cure were noted in 
123 (81 %) of the 152 patients. Side effects included nausea in five (3%) patients, 
sensation of distended abdomen in one (I%), nausea and headache in one (I%) and 
fatigue in three (2%). The only abnonnallaboratory fmding was a slight increase in 
SGOT and SGPT values in one patient. 
Of the 110 patients treated with 2 x !50 mg roxithromycin daily (Table !), 32 
(29%) could not be evaluated due to failure to report for follow-up in 25 (78%) 
cases, sexual contact in two (6%), no chlamydia culture at follow-up in three (19%), 
improper drug intake in one (3%) and no Neisseria gonorrhoeae culture at the start 
of the study in one (3%). 
The 78 patients available for evaluation included 22 (28%) in whom Chlamydia 
rrachomaris and 30 (38%) in whom Ureaplasma urealyricum was isolated from the 
urethra. After treatment all of the 22 patients with formerly positive Chlamydia 
rrachomatis cultures and 23 (77%) of the 30 patients with formerly positive 
Ureaplasma urealyticum cultures had negative cultures. Clinical cure was observed 
in 70 (90%) of the 78 patients. Ureap/asma urealyricum was isolated in one 
clinically cured patient with a negative urinary sediment. Both a negative urinary 
sediment and a clinical cure was noted in 49 ( 63%) of the 78 patients. Side effects 
included nausea in two patients (3%) and headache in one patient (I%). One patient 
had a slightly increased SGOT value and three patients a slightly increased total 
bilirubin concentration. 
At statistical analysis both within and between groups, only the difference 
between clinically cured patients with a negative urinary sediment was statistically 
in favour of a single dose of 300 mg (p< 0.01). 
DISCUSSION 
The clinical cure rates obtained with both dosage regimens (90%) are within the 
range reported for tetracyclines of 70-90% (10-13). Unlike Bowie (13) we were not 
able to demonstrate a more favourable therapeutic result in patients with cultures 
positive for Chlamydia rrachomaris and/or Ureaplasma urealyricum compared to 
those with negative cultures. Due to the latency or temporary suppression of the 
organism seen in Chlamydia trachomatis infections, the cure rate obta.ined 
immediately after therapy might be higher than would have been the case with a 
follow-up period of two weeks. However, Bowie (13) demonstrated that none of 24 
men who had become Chlamydia trachomatis negative after a seven day course of 
1 g tetracycline daily were positive again after a follow-up period of more than two 
weeks. Arya (12) demonstrated that relapses occured after 3 to 4 weeks in II of 62 
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patients and after 5 weeks in 64 of 90 patients who admitted sexual contact during 
tlris period. 
The fact that the difference between the clinically cnred patients with a negative 
urinary sediment was statistically significant in favour of the 300 mg dose may 
reflect better tissue penetration when a higher single dose is administered, with a 
consequently more pronounced anti-bacterial effect. 
The mild side effects reported by 5% of the patients were never a reason for 
discontinuation of treatment. Roxithromycin would thus seem to be effec~ve in the 
treatment of non-gonococcal urethritis in males, and suitable for use as an alternative 
to tetracycline and erythromycin. 
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SUMMARY 
In a randomized study the clinical efficacy of ciprofloxacin was compared with 
that of doxycycline administered in two different dosage schemes to male patients 
suffering from non-gonococcal urethritis. Fourteen days after completion of therapy 
(day 21) pyuria was absent in 30 of I 00 patients in the ciprofloxacin group; 
Chlamydia trachomatis was isolated from five and Ureaplasma urealyticum from 
eight patients. In the 100 mg doxycycline group (n;60) pyuria was absent in 36 
patients (60%) and Ureaplasma urealyticum was isolated from six patients on day 
21. In the 200 mg doxycycline group (n;45) pyuria was absent in 18 patients (40%) 
and Ureaplasma urealyticum was isolated from two patients on day 21. Side effects 
were mild and transient in all groups. It is concluded that ciprofloxacin given in a 
dosage of I g for seven days is not effective in the treatment of non-gonococcal 
urethritis. 
INTRODUCTION 
Epidemiological research into the prevalence of genital pathogens in male patients 
attending a venereological out -patient clinic revealed that Chlamydia trachomatis 
was isolated in 30% and Ureaplasma urealyticum in 30%. It was also found that up 
to 40% of the men suffering from gonorrhoea were also infected with Chlamydia 
trachomatis (I). These percentages indicate that Chlamydia trachomatis and perhaps 
also Ureaplasma urealyticum play an important role in the aetiology of sexually 
transmitted diseases. 
Ciprofloxacin, one of the new quinolones, is effective against Neisseria 
gonorrhoeae both in vitro and in vivo (2). The MIC values of ciprofloxacin for both 
Chlamydia trachomatis and Ureaplasma urealyticum range from 0.5 to 2 J.lg/ml (3). 
J\n agent which could cure both gonorrhoeae and chlamydia! infections is becoming 
more and more desirable. Moreover, an addition to the current drugs used in the 
treatment of non-gonococcal urethritis (tetracyclines or macrolides (4)) would be 
welcome. Ciprofloxacin is a possible candidate (5). In a randomized study the 
clinical efficacy of ciprofloxacin versus doxycycline administered in two different 
dosage schemes was tested in male patients suffering from non-gonococcal urethritis. 
MATERIALS AND METHODS 
All patients were men attending the outpatient clinic for sexually transmitted 
diseases at the University Hospital Rotterdam-Dijkzigt. Patients younger than 18 
were excluded, as were patients with a history of allergy to tetracycline or 
carboxyquinolone derivatives, those with severe liver and kidney disease, those with 
nnderlying conditions making it unlikely that treatment with the test drugs and 
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follow-up could be completed, and those likely to require treatment with a con-
comitant antimicrobial agent with a range of activity similar to that of the test drugs. 
Three hundred and eight patients were enrolled in the study; 155 patients were 
treated with ciprofloxacin and 153 with doxycyline. In the first part of the study a 
randomisation list ensured that patients received either 1 g ciprofloxacin in a single 
oral dose daily for seven days or 200 mg doxycycline on day 1, followed by 100 mg 
daily for six days. In the second part of the study a randomisation list ensnred that 
patients received either I g ciprofloxacin daily for seven days or 2 x I 00 mg 
doxycycline daily for seven days. Patients were advised to abstain from sexnal 
contacts or to use condoms throughout the follow-up period of three weeks. All 
subjects gave oral informed consent before enrollment. The study was approved by 
the committee for the protection of human subjects at the University Hospital 
Rotterdam-Dijkzigt. 
A standard history was taken and all patients submitted to the following tests 
before and one day after completion of therapy (day 8): Gram stain of urethral 
discharge and culture of urethral samples for Ureaplasma urealyticum (6-9), 
Chlamydia trachomatis (6,10) and Neisseria gonorrhoeae (6), test of blood samples 
for treponema! antibodies (ouly before therapy), general haematological tests and 
blood chemical analysis. The sediment of the frrst 10-15 ml urine was collected 
when the patient had not voided for 4 h or longer. 
Non-gonococcal urethritis was diagnosed if more than ten leucocytes were 
observed in the sediment at a magnification of 250 times and if the Gram stain 
revealed no intracellular Gram-negative diplococci. At the control visit urinary 
sediment was examined by microscopy for the presence of casts and crystals. 
Clinical cure was defmed as the disappearance of complaints following therapy. 
Bacteriological cure was defmed as a negative culture following therapy. At the fust 
assessment (day 8) all patients were asked whether they had experienced any side-
effects. The patients whose pyuria was cured were asked to report back for a follow-
up two weeks after completion of therapy. At this third visit (day 21) the previously 
performed tests were repeated except for the blood analysis. At both control visits 
all patients were asked whether dysuria and/or discharge were still present. The 
results were analysed statistically by applying Fisher's one-tailed exact test. 
RESULTS AND DISCUSSION 
Table I sununarizes the reasons why patients could not be included in this study. 
The results of Chlamydia trachomatis and Ureaplasma urealyticum cultures, and the 
incidence of resolution of pyuria and clinical cure in the assessable patients are 
summarized in Table 2 and 3. Of the total of 155 male patients treated with I g 
ciprofloxacin, 55 (35%) were not assessable (Table 1); 100 patients were bacterio-
logically assessable and I 0 I patients were assessable with respect to side effects. Of 
the nine patients who were Ureaplasma urealyticum positive on day 21 (Table 3) 
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Table 1. Non..assessable patients treated with ciprofloxacin and doxycycline. 
Reason for non~assessment Ciprofloxacin Doxycycline 
Sexual contact 8 
Failure to return for assessment 22 22 
Failure to return for follow-up 9 16 
Failure to take medication 6 0 
Gonorrhoea 3 2 
No gonococcal culture at start of study 1 0 
No control C. trachomatis culture 5 7 
Recent syphilis 0 
Total 55 48 
one was positive only on that day, one had first become positive one day after 
completion of therapy, five had relapses, and two had been positive throughout. Of 
the eight patients who were positive for Chlamydia trachomatis on day 21, three 
were positive only on that day and five had relapses. Ten patients had a positive 
culture for Chlamydia trachomatis or Ureaplasma urealyticum without sediment 
changes on day 21. 
Of the total of 153 patients treated with doxycycline, 48 were not assessable 
(Table 1). In the 100 mg doxycycline group, 60 patients were bacteriologically 
assessable and 63 patients were assessable with respect to safety. Of the eight 
patients who were Ureapla.sma urealyticum positive on day 21 (Table 3) two were 
positive only on that day. One had first become positive one day after completion 
of therapy, three had relapses and two had been positive throughout. One patient 
was positive for Chlamydia trachomatis on day 21. Three patients had a positive 
culture for Chlamydia trachomatis or Ureaplasma urealyticum without sediment 
changes on day 21. 
In the 200 mg doxycycline group 45 patients were bacteriologically assessable and 
4 7 were assessable with respect to side-effects. Of the three patients who were 
positive for Ureaplasma urealyticum on day 21 (Table 3), one was positive only on 
that day, one had a relapse and one had been positive throughout. One patient had 
a positive culture without pyuria on day 21. 
One of the 10 I patients ( 1%) treated with ciprofloxacin had abdominal pain. 
Abnormal laboratory fmdings included slightly increased alkaline phosphatase, 
SGOT and SGPT values in one case, and slight anisocytosis in one case. Side 
effects and abnormal laboratory fmdings were not observed .in the 100 mg 
doxycycline group. 
One of the 4 7 patients treated with 200 mg doxycycline showed a photoallergic 
reaction, one complained of abdominal pain, one of vertigo and one of general 
malaise. Abnormal laboratory fmdings included slightly increased total bilirubin, 
SGOT and SGPT values in one case, a slightly total bilirubin value in one case, and 
slightly increased total bilirubin and SGPT values in one case. 
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Table 2. Results of antimicrobial therapy in males with non-gonococcal urethritis after 8 days. 
Oral therapy No. of Culture before therapy Bacteriological cure Resolution Clinical 
patients C. tracho- U. urealy- C. tracho- U. urealy- of pyuria 
cure 
rna tis ticum matis ticum 
Ciprofloxacin 100 32/100 32/100 29/32 28/32 44/100 74/100 
lgx7days (+ l)a (+ 1)" 
Doxycycline 60 15/60 20/60 14/15 15/20 44/60 50{60 
200 mg x 1 day (+ l)a (+ l)a 
100 mg x 6 days 
Doxycycline 45 13/45 20/45 13/13 18/20 23/45 36/45 
2 X 100 mg X 
7 days 
a Number of cultures not previously positive. 
Table 3. Results of antimicrobial therapy in males with non-gonococcal urethritis after 21 days. 
Oral therapy No. of Culture before therapy Bacteriological cure Resolution Clinical 
patients C. tracho- U. urealy- C. tracho- U. urealy- of pyuria cure 
rna tis ticum matis ticum 
Ciprofloxacin 100 32/100 32/100 24/32 23/32 30/100 35/100 
lgx7days 
Doxycycline 60 15/60 20{60 14/15 12/20 36/60 38/60 
200 mg x 1 day 
100 mg x 6 days 
Doxycycline 45 13/45 20/45 13/13 17/20 18/45 20/45 
2 X 100 mg X 
7 days 
Statistical analysis disclosed significant differences only between the group given 
ciprofloxacin and the group given 200 mg doxycycline on day 1 followed by 100 
mg daily for six days, in tenns of resolved pyuria one day (44% versus 73%) and 
14 days (30% versus 60%) after completion of therapy (p < 0.01). A difference in 
cure rate between Chlamydia trachomatis and/or Ureaplasma urealyticum positive 
and negative non-gonococcal urethritis was not observed. 
Nor was a difference seen between the bacteriological and clinical cure rates in 
the three treatment groups. 
In view of the bacteriological and clinical fmdings after three weeks, it is evident 
that neither ciprofloxacin nor doxycycline in dosages administered in thls study are 
sufficient to cure non-gonococcal urethritis. 
An interesting Imding is the decreasing rates of clinical cure and resolution of 
pyuria observed in non-gonococcal urethritis patients treated with doxycycline. The 
factors responsible are not known. 
A possible reason for the low efficacy of ciprofloxacin in the treatment of non-
gonococcal urethritis is underdosage. Another possible reason is insufficient duration 
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of treatment. It has been reported (11) that a dosage of 500 mg ciprofloxacin given 
twice daily for ten days was effective in the treatment of non-gonococcal urethritis. 
A clinical study (12) comparing the efficacy of 750 mg ciprofloxacin twice daily 
versus 100 mg doxycycline twice daily for seven days revealed no differences in the 
clinical and bacteriological cure or relapse rates in non-gonococcal urethritis 
patients. An earlier study (13) using a dosage of 500 mg ciprofloxacin twice daily 
for seven days revealed a cure rate of 22% in patients suffering from Chlamydia 
trachomatis positive urethritis. 
Although the bacteriological cure rates in our three treatment groups were within 
the range reported in the literature of 70-90% (14-16), in terms of resolution of 
pyuria and clinical cure the rates were lower in all three treatment groups. A study 
(14) using the same doxycycline regimens as those used in our study showed no 
difference between the two groups in the clinical and bacteriological cure rate in 
male patients suffering from non-gonococcal urethritis. Evaluation took place one 
day after completion of treatment. Although not statistically significant, the results 
in terms of resolution of pyntia are better in our study in the 100 mg doxycycline 
group than the 200 mg doxycycline group. Futher studies are necessary to com1m1 
these fmdings. Side-effects and laboratory changes were minimal in numher and of 
a transient nature in the three treatment groups in our study. 
In conclusion, ciprofloxacin administered in a dosage of 1 g for seven days is not 
sufficiently effective in the treatment of non-gonococcal urethritis in male patients. 
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fu evaluating new therapies for treatment of sexually transmitted diseases it is 
necessary to examine carefully patients in whom treatment fails in order to rule out 
factors as poor compliance in taking medication or continued sexual contact during 
the study period. Alternatively, development of antimicrobial resistance in the 
microorganism involved may acconnt for treatment failure. In this study we 
investigated cases of treatment failure occurring in an earlier therapy study of 
patients with non-gonococcal urethritis who were treated with ciprofloxacin or 
doxycycline (1). Randomly selected Chlamydia trachomatis strains isolated before 
therapy and all available pairs of strains isolated before and after therapy with either 
drug were serotyped, and the in vitro activity of these two drugs and erythromycin 
against the strains was determined. 
Five Chlamydia trachomatis strains isolated only before therapy with cipro-
floxacin or doxycycline were serotyped and the MICs and tviBCs of ciprofloxacin, 
erythromycin and doxycycline for these strains determined. Likewise, serotype, MIC 
and MBC were determined for four pairs of strains isolated before and after therapy 
with ciprofloxacin (I g daily in a single oral dose for seven days) and one strain 
isolated before and after therapy with doxycycline (200 mg on day 1, followed by 
100 mg daily for six days). 
The MIC of each drug was determined using the method described by Segreti et 
al (2). DEAE-dextran treated McCoy cells were inoculated with 103-104 inclusion-
forming units of each chlamydia! isolate per well, centrifuged for 60 min, and 
incubated at 37°C in a 5% C02 atmosphere for 2 days. The inocnlum was then 
replaced with cnlture media (0.1 ml per well) containing serial twofold dilutions of 
each antimicrobiol agent and 0.1 flg/ml cycloheximide. 
The drugs were diluted from 16 to 0.015 flg/ml. After 48h of incubation two wells 
per dilution were fJXed and stained with a fluorescine-conjugated monoclonal 
antibody to Chlamydia trachomatis (3). The MIC was defmed as the lowest 
concentration at which 90% inhibition of inclusion body formation was observed. 
The remaining wells were incubated for another 48h in culture media without 
antibiotics. The l\1BC was defmed as the lowest concentration of antimicrobial agent 
yielding no inclusions after passage (2). 
Staphylococcus aureus ATCC and 25923 and 29212, Escherichia coli ATCC 
25922 and Pseudomonas aeruginosa ATCC 27853 with known MIC values for the 
test drugs were used as control strains. 
The culture medium containing suspended Chlamydia trachomatis and host cell 
debris was centrifuged at 11.000 x g for 15 minutes. The resulting pellet was 
suspended in phosphate buffered saline (of pH 7.6 containing 0.02% formalin). 
Suspensions of prototype antigens or clinical isolates to be typed were applied to 
nitrocellulose membranes and dried. The dot enzyme immunoassay for serotyping 
was performed as described perviously (4). 
The MICs of doxycycline before treatment were 0.06-0.25 flg/ml (Table 1). 
Unfortunately the only posttreatment strain in the doxycycline group died in 
storage and could not be tested further. The MICs of ciprofloxacin before and after 
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Table 1. Serotypes of and MICs of doxycycline, ciprofloxacin and erythromycin for five Chlamydia 
trachomatis strains isolated only before antibiotic treatment or before and after treatment. 
Therapeutic MIC (eg/ml) 
Agent Serotype Ciprofloxacin Doxycycline Erythroycin 
Before After Before After Before After Before After 
Ciprofloxacin D 2 0.25 0.5 
I 2 0.12 0.25 
E 2 0.25 0.5 
H 2 0.12 0.25 
F 2 0.06 0.25 
K K 2 2 0.25 0.25 0.5 0.5 
l l 0.12 0.12 0.25 0.25 
F F 2 2 0.25 0.25 0.12 0.12 
D D 2 2 0.25 0.25 0.12 0.12 
Doxycycline D 2 0.12 0.25 
E 2 0.06 0.25 
E 2 0.12 0.25 
D 2 0.12 0.25 
J J 0.12 0.25 
G 0.12 0.5 
2 $train not viable for testing. 
therapy were 1-2 f!g/ml (Table 1). No elevation of MICs was observed in the strains 
isolated after treatment. The MICs of erythromycin for all strains were 0.12-0.5 
f!g/ml (Table !). All of the MIC and MBC values determined in this study were 
identical or within one dilution step. 
All strains isolated before and after therapy were of the same serotype (Table 1). 
The MIC values of doxycycline, ciprofloxacin and erythromycin were within the 
ranges previously reported (5). 
The fact that the pre-treatment and post-treatment strains were the same does not 
rule out a new infection, but makes it less probable, as condom use was advised 
during the treatment and follow-up period. Thus we conclude that these cases should 
be regarded as genuine instances of treatment failure of ciprofloxacin without 
development of resistance. 
Recently, Jones et a!. (6) isolated Chlamydia trachomaris strains resistant to 
tetracycline from five patients. These isolates were also resistant to doxycycline and 
erythromycin. The clinical significance of this resistance is not lmown. 
To our lmowlegde, there are no reports of resistance to ciprofloxacin in 
Chlamydia trachomatis. 
Although successful treatment of Chlamydia trachomatis infections with 
ciprofloxacin depends not only on the MIC/MBC values but also on other 
pharmacokinetic parameters, clinical studies have demonstrated that ciprofloxacin 
in increasing dosages did not display increased efficacy (1,7,8). 
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Thus the fmdings in this investigation support our previous conclusion that C. 
trachomatis infections in these patients were not cured with ciprofloxacin therapy 
(1). 
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In view of the AIDS catastrophe, one may question whether research into the 
causes and the treatment of sexually transmitted urethritis is still meaningful. In my 
personal opinion, it is far from it. All sexually transmitted diseases including lUV 
infections are closely related to each other as far as their history, biology, 
behavioural science, economics and therapeutics are concerned [1]. Worldwide, 
Gonorrhea is the most common veneral disease. In the Western World, non-
gonococcal urethritis (NGU) is the most common bacterial Sexually Transmitted 
Disease (STD). 
Historically, it appears that the incidence of gonococcal infections occurs in waves 
and serves as a scale for measuring the changes in sexual behaviour [2]. The 
downward trend in gonococcal infections of the past years has recently reversed into 
an upward trend [3]. Since, vaccination against gonococcal infections is unavailable 
at present and will not be available in the near future, treatment with antibiotics 
remains essential [ 4]. 
The fact that N. gonorrhoeae are able to survive for prolonged periods in an 
untreated patient and frequently infect the same individiual again makes this micro-
organism a ''survivor"' [5]. At present, it appears that inspite of the worldwide use 
of protocoled treatment strategies, it has not yet been possible to check the problem 
of gonorrhea. The number of resistant and multiple resistant gonococcal strains has 
increased steadily [3,6,7]. In the game of chess between the new antibiotics and the 
development of resistance, N. gonorrhoeae appear to have the upper hand. 
Resistance against quinolones (a new group of drugs for treating gonorrhea), first 
reported by us for enoxacin, is being increasingly reported in the international 
literature [8]. Resistance against ciprofloxacin has been reported in different studies 
[9,10]. Development of resistance against norfloxacin has also been reported [11]. 
The second group of drugs that occupy a prominent place for treating gonorrhea are 
the cepha1osporins. The reduced susceptibility of gonococci for this group of 
antibiotics in vitro is of great concern [12]. In vivo resistance to cephalosporins has 
not yet been reported. 
The knowledge that at present there is no new group of antibiotics which is able 
to eliminate the newly arising highly resistant N. gonorrhoeae strains appears to 
present a rather gloomy picture for the treatment of gonorrhea in the future. 
Another noteworthy point is the frequent occurrence of mixed infections of N. 
gonorrhoeae with C. trachomatis (about 15%). 
To date, infection caused by C. trachomatis is the most common bacterial STD 
in the Western World. 
It has been estimated that between 35 and 60% of the NGU cases are caused by 
C. trachomatis. At present, this figure is somewhere between 15 and 20%. 
The possible polymicrobial aetiology of NGU often pose therapeutic problems. 
Even when the therapy of NGU is strictly according to the protocol, treatment-
failures still occur in a not to be neglected group of patients [13]. 
At present, the therapy of NGU is mainly directed at eliminating C. trachomatis 
infections. 
118 Chapter 11 
Taking into account that C. trachomatis is a frequent causative agent of NGU, the 
complications that arise and the checkable follow-up after treatment suggest that this 
approach for dealing with NGU is both useful and essential. In fact, the problem is 
clearly more complicated. The persistent and recurrent NGU presents a dilemma 
which cannot be easily resolved since the exact causative agent(s) remains elusive 
[14]. 
Recently, resistance of C. trachomatis strains against erythromycin, tetracycline 
and other antibiotics has been reported [15]. Although the clinical implication of this 
is not yet clear, it should be taken into account, there will be problems in treating 
infections caused by these strains in the future. Evaluation of new drugs for treating 
NGU are progressing. The new quinolones which are effective against C. 
trachomatis in vitro appear not to offer any distinct clinical advantage andjor are 
observed to be less effective as compared with other normally used therapies. 
Another group of drugs, the new macrolides are as effective as other normally used 
therapies. Azithromyc:in has the advantage that the period of treatment can be 
shortened by 1 to 3 days. To date, this drug has mostly been clinically evaluated in 
patients with C. trachomatis positive urethritis. Whether the same results would be 
obtained in NGU as a whole remains to be investigated. 
The coincidence of gonococcal and non-gonococcal urethritis, the nature of the 
patient population in relation to therapy compliance and check-ups, the size of the 
problem, the resulting complications and the development of resistance by the micro-
organisms justify the view to return to the old thinking that sexually transmitted 
urethritis is a single disease. The solution would be a single dose of one drug or a 
cocktail of drugs administered to a patient with urethritis. However, that is not to say 
that culturing of the different causative agents, the determining of antibiograms, the 
research into vaccins and the development of new drugs should be discontinued. 
SUMMARY 
Chapter 1 
In this chapter, a historical survey of sexually transmitted urethritis is presented. 
The different causative agents, the clinical presentations and the complications are 
all discussed. A review of different therapies and the problems encountered through 
the years is presented. The development of drug-resistance by the causative microbes 
is discussed in detail. The epidemiology of gonorrhea, C. trachomatis and NGU is 
described. A literature survey of new drugs for treating gonorrhea, the quinolones 
and the third generation and oral cephalosporins is presented and discussed with 
respect to their in vitro effectiveness against N. gonorrhoeae, their clinical efficacy 
and their side-effects. 
At the same time, a literature survey on new drugs for treating NGU and C. 
trachomatis infections is also presented. The quinolones and new macrolides are 
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discussed in relation to their in vitro effectiveness against C. trachomatis and U. 
urealyticum, their clinical efficacy and their side-effects. 
Chapter 2 
In a double-blind randomized study, !55 male patients with uucomplicated 
urethral gonorrhea were given 200 mg (n ~ 77) or 400 mg (n ~ 78) of enoxacin 
orally. The cure rates in the 200- and 400-mg treatment groups were 90 and 92%, 
respectively. The enoxacin MIC for the isolated N. gonorrhoeae strains ranged from 
0.015 to 0.12 1-lg/ml. Postgonocccal urethritis was diagnosed in 29 (42%) patients 
in the 200-mg treatment group and 19 (26%) patients in the 400-mg treatment group. 
Side effects (nausea, headache, and vontiting) occurred in 2 (3%) of the 77 patients 
in the 200-mg treatment group and in 3 (4%) of the 78 patients in the 400-mg 
treatment group. 
Chapter 3 
Uncomplicated urogenital and concomitant oropharyngeal gonorrhea in 424 male 
and female patients was treated in a randomized comparative study with 0.5 g of 
cefodizime (89 men and 54 women), 1 g of cefodizime (87 men and 52 women), or 
1 g of cefotaxime (86 men and 56 women). The cure rates were 100% for men and 
women in the group given 0.5 g of cefodizime, 100% for men and women in the 
group given 1 g of cefodizime, and 99% for men and 100% for women in the group 
given 1 g of cefotaxime. The MICs of cefodizime and cefotaxime for the isolate of 
N. gonorrhoeae ranged from 0.004 to 0.06 f!g/ml. C. trachomatis was isolated 
before treatment in !5% and after treatment in !3% of all patients. Side effects, such 
as nausea, diarrhea, abdominal pain, genital candidiasis, and pain at the site of 
injection, developed in 4% of the patients given cefodizime. Side effects, such as 
vertigo, genital candidiasis, fatigability, and diarrhea, developed in 4% of the 
patients treated with cefotaxime. In both groups of patients, the side effects were 
mild and transient. Cefodizime and cefotaxime are safe and effective agents in the 
treatment of uncomplicated urogenital gonorrhea. 
Chapter 4 
Ten male patients suffering from uncomplicated urethral gonorrhoea were treated 
orally with !200 mg Ceftetrame. Nine of the 10 patients were cured. The sensitivity 
of the isolated N. gonorrhoeae strains to Ro 19-5247, the active metabolite of 
Ceftetrame, ranged from < 0.002 to 0.12 !lg/ml. 
C. trachomatis was isolated before and after treatment in one patient. No side 
effects were reported. Ceftetrame is an effective drug in the treatment of un-
complicated urogenital gonorrhoea in males. 
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Chapters 5 and 6 
The development of resistance of N. gonorrhoeae against the new quinolones and 
the crossresistance of N. gonorrhoeae to various quinolone derivatives are discussed 
here. 
Chapter 7 
The in vitro actiVltles of ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, 
norfloxacin, ofl.oxacin and pefloxacin against 10 penicillinase-producing N. 
gonorrhoeae strains (PPNG's) 10 non PPNG's, 10 non-penicillinase-producing 
penicillin-resistant chromosomally mediated N. gonorrhoeae strains (CMRNG's), 3 
N. gonorrhoeae strains with a decreased sensitivity against quinolones compounds 
and one tetracycline resistant penicillinase-producing N. gonorrhoeae (TRNG/PPNG) 
strain were evaluated in this study. The non PPNG, PPNG, CMRNG and TRNG/ 
PPNG strains showed good to excellent sensitivity to the quinolones tested. The N. 
gonorrhoeae strains with a decreased sensitivity against quinolones showed higher 
MIC values. 
Chapter 8 
One-hundred and fifty-two male patients suffering from non-gonococcal urethritis 
were treated with an oral dose of 300 mg roxithromycin daily for seven days. C. 
trachomatis was isolated from the urethra in 53 patients (35%), and U. urealyticum 
in 42 patients (28%). After treatment, 49 (92%) of the 53 patients with positive C. 
trachomatis cultures and 34 (81 %) of the 42 patients with positive U. urealyticum 
cultures had negative cultures at follow-up. A clinical cure was observed in 137 
patients (90%). Ten patients (7%) showed side effects consisting of nausea, 
sensation of distended abdomen, headache and fatigue. Seventy-eight male patients 
suffering from non-gonococcal urethritis were treated with an oral dosage of 2 x 150 
mg roxithromycin daily for seven days. 
C. trachomatis was isolated from the urethra in 22 patients (28%), and U. 
urealyticum in 30 patients (38%). After treatment, all of the 22 patients with 
formerly positive C. trachomatis cultures and 23 (77%) of the 30 patients with 
formerly positive U. urealyticum cultures were negative at follow-up. A clinical cure 
was observed i11 70 patients (90%). Three patients (4%) showed side effects 
consisting of nausea and headache. It is concluded that roxithromycin is a good 
alternative to tetracycline and erythromycin in the treatment of non-gonococcal 
urethritis in males. 
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Chapter 9 
In a randomized study the clinical efficacy of ciprofloxacin was compared with 
that of doxycycline administered in two different dosage schemes to male patients 
suffering from non-gonococcal urethritis. Fourteen days after completion of therapy 
(day 21) pyuria was absent in 30 of 100 patients in the ciprofloxacin group; C. 
trachomatis was isolated from five and U. urealyticum from eight patients. In the 
I 00 mg doxycycline group (n ~ 60) pyuria was absent in 36 patients (60%) and U. 
urealyticum was isolated from six patients on day 21. In the 200 mg doxycycline 
group (n ~ 45) pyuria was absent in 18 patients (40%) and U. urealyticum was 
isolated from two patients on day 21. Side effects were mild and transient in all 
groups. It is concluded that ciprofloxacin given in a dosage of 1 g for seven days 
is not effective in the treatment of non-gonococcal urethritis. 
Chapter 10 
In this chapter, the susceptibility of C. trachomatis strains isolated in the study 
described in chapter 9 for ciprofloxacin, doxycycline and erythromycin are 
determined. At the same time five strains which were isolated before, and the strains 
that were isolated before and after therapy were sero-typed. The MICs for these 
three antibiotics corroborated well with those reported in the literature. 
REFERENCES 
1. W. Cates, A.R. Hinman. Sexually transmitted diseases in the 1990s. N. Engl. J. Med, 325:1368-1370, 
1991. 
2. P. French, J. Davis, D. Goldmeier. Trends in gonococcal infection: no room for complacency. 
Genitourin Med 66:302-305, 1990. 
3. C.J.M. Henquet, P.G.H. Peerbooms, G.J.J. van Doomum, R.A. Coutinho. Stijging van het aantal 
gevallen van gonorroe in Amsterdam met een toenemende resistentie tegen antibiotica. Ned Tijdschr 
Geneek 135:950. 1991. 
4. J.S. Moran, J.M. Zenilman. Therapy for gonoccal infections: options in 1989. Rev Infect Dis 12, 
Suppl 6o5633-5644. !990. 
5. P.F. Sparling, J. Tsai, C.N. Cornelissen. Gonococci are survivors. Scand J Infect Dis, Suppl 
69:125-136. 1990. 
6. C.S.F. Easmon. The changing pattern of antibiotic resistance of Neisseria gonorrhoeae. Gentitourin 
Med 66:55-56, 1990. 
7. I. Lind. Epidemiology of antibiotic resistant Neisseria gonorrhoeae in industrialized and developing 
countries. Scand J Infect Dis, Suppl 69:77-82, 1990. 
8. J.H.T. Wagenvoort, A.H. van der Willigen. H.J.A. van Viet, M.E Michel, B. van Klingeren. 
Resistance of Neisseria gonorrhoeae to enoxacin. J. Antimicrob Chemother 18:429, 1986. 
9. A. Turner, A.E. Jephcott, T.C. Haji, P.C. Gupta. Ciprofloxacin resistant Neisseria gonorrhoeae in the 
UK. Genitourin Med 66:43, 1990. 
10. W.R. Gr:msden, C.A. Warren, I. Philips, M. Hodges, D. Barlow. Decreased susceptibility of Neisseria 
gonorrhoeae to ciprofloxacin. The Lancet 335:51, 1990. 
122 Chapter 11 
11. K.H. Yeung, J.R. Dillon. Norfloxacin resistant Neisseria gonorrhoeae in North America. The Lancet 
336o759, 1990. 
12. C.A. !son, K.M. Bindayna, R. Woodford, M.J. Gill, C.S.F. Easmon. Penicillin and cephalosporin 
resistance in gonococci. Genitourin Med 66:351-356, 1990. 
13. K.E. Tooney,R.C. Barnes. Treatment of Chlamydia trachomatis genital infection. Rev. Infect Dis 12, 
supp1 6o5645-5655, 1990. 
14. Th.M. Hooton, ES. Wong, R.C. Barnes, P.L Roberts, W.E. Stamm. erythromycin for persistent or 
recurrent non-gonococcal urethritis. Ann Intern Med 113:21-26, 1990. 
15. G.R.B. Jones, B. van der Pol, D.H. Martin, M.K. Shepard. Partial characterization of Chlamydia 
trachomatis resistant to multiple antibiotics, J Infect Dis 162:1309-1315, 1990. 
Chapter 11 123 
SAMENVATTING 
Men kan zich afvragen of, in het Iicht van de AIDS catastrofe, onderzoek naar de 
oorzaak en behandeling van sexueel overdraagbare urethritiden nog wel zinvol is. 
Niets is mijns inziens minder waar. Aile sexueel overdraagbare aandoen.ingen, 
inclusief HIV infecties, zijn historisch, biologisch, gedragswetenschappelijk, 
econontisch en therapeutisch nauw met elkaar verbonden [1]. Wereldwijd is 
gonorroe de meest voorkomende geslachtsziekte. In de westerse wereld is NGU de 
meest voorkomende bacteriele SOA. 
Historisch gezien blijkt de incidentie van gonorrolsche infecties een golfbeweging 
te beschrijven en een graadmeter te zijn voor veranderingen in sexueel gedrag [2]. 
De neergaande lijn van het aantal gonorroische infecties van de afgelopen jaren is 
recentelijk omgebogen naar een opwaartse [3]. Omdat vaccinatie tegen N. 
gonorrhoeae infecties nog niet op korte termijn te verv.rachten valt, blijft behan-
deling met antibiotica noodzakelijk [4]. 
Het feit dat de gonococ in staat is gedurende langere tijd in de onbehandelde 
patient te overleven en frequent eenzelfde persoon kan besmetten, maakt dit micro-
organisme tot een -overlever" [5]. Op dit moment is het, ondanks wereldwijde 
protocollaire behandelingsstrategieen, niet mogelijk gebleken het gonorroe probleem 
in te dammen. Het aantal resistente en multipel resistente gonococcen stammen 
neemt overhand toe [3,6,7]. In het schaakspel van nieuw antibioticum en resistentie-
vorming lijkt de gonococ in het voordeel te zijn. 
Resistentie tegen quinolonen, een nieuwe geneesmiddelengroep bij de behandeling 
van gonorroe, door ons voor het eerst beschreven voor enoxacin, wordt steeds vaker 
gemeld in de internationale literatuur [8]. Resistentie tegen ciprofloxacin werd 
verschillende malen beschreven [9,10]. Ook voor norfloxacin is resistentie vonning 
beschreven [ 11]. 
De tweede groep geneesntidde!en die een voorname p!aats innemen bij de 
behandeling van gonorroe zijn de cephalosporinen. De venninderde in vitro 
gevoeligheid van de gonococ voor deze groep antibiotica baart grote zorgen [12]. 
In vivo resistentie is echter nog niet gemeld. 
Het gegeven dat er op dit moment geen nieuwe groep antibiotica is, die in staat 
is de opkomende hoog resistente gonococcen stammen te elimineren stemt somber 
wat betreft de behandeling van gonorroe in de toekomst. 
Een ander aandachtspunt is het veelvuldig voorkomen van menginfecties van N. 
gonorrhoeae met C. trachomatis (ongeveer 15 procent). 
Infecties veroorzaakt door C. trachomaris zijn heden de meest voorkomende 
bacteriele SOA in de W esterse Wereld. 
Het aandeel van C. trachomatis, als verwekker van NGU werd geschat tussen de 
35 en 60 procent en ligt op dit moment tussen de 15 en 20 procent. 
De mogelijk pclynticrobie!e aetiologie van NGU veroorzaakt therapeutische 
problemen. Ook a! is de behandeling van NGU protocolair vastgelegd toch faalt 
deze behandeling bij een niet te verwaarlozen groep [13]. 
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De therapie van NGU wordt op dit moment toegespitst op C. trachomatis 
infecties. 
Met het oog op het veelvuldig voorkomen van C. trachomatis als verwekk:er van 
NGU, de bijkomende complicaties en de controleerbare follow-up na behandeling, 
is deze benadering van het NGU probleem nuttig en wezenlijk. Echter het probleem 
is duidelijk complexer. Het voorkomen van persisterende en recid.iverende NGU is 
een niet weg te cijferen dilemma [14], omdat de verwekker(s) onbekend zijn. 
Recentelijk werd er melding gemaak.-t van resistentie van C. trachomatis stammen 
tegen erythromycine, tetracycline en andere antibiotica [15]. Alboewel de klinische 
relevantie hiervan nog niet duidelijk is, moet in de toekomst met behandelings-
problemen bij infecties met dit soort stammen rekening worden gehouden. 
De evaluatie van nieuwe geneesmiddelen bij de behandeling van NGU is LJ. voile 
gang. De nieuwe quinolonen met een goede in vitro activiteit tegen C. trachomatis 
blijken in de pral.-tijk bij klinische studies geen duidelijke voordelen te bieden enjof 
slechtere resultaten te geven in vergelijking met de gebruikelijke therapieen. Een 
andere groep geneesmiddelen, de nieuwe macroliden, voldoen even goed als de 
gangbare therapieen. Azithromycin heeft als voordeel, dat de behandelingsduur 
verkort kan worden van 1 tot 3 dagen. Tot nu toe vond klinische evaluatie hoofd-
zakelijk plaats bij C. trachomatis positieve urethritis. Of dezelfde resultaten zouden 
zijn behaald bij NGU als geheel blijft de vraag. 
Het samengaan van gonorrolsche en niet-gonorroische urethritis, met betrekking 
tot de aard van de patienten-populatie, therapie-trouw, controle-bezoek, en de 
omvang van het probleem, met de er uit voort vloeiende complicaties en resistentie-
vorrning van de betrokken micro-organismen, rechtvaardigen het denkbeeld terug te 
grijpen op de oude gedachte dat sexueel overdraagbare urethritis een ziektebeeld is. 
De oplossing zou zijn, een eerunalige gift van een geneesmiddel of een cocktail van 
geneesrniddelen. Dit wil niet zeggen dat bet kweken van de verschillende 
verwekkers, het bepalen van het antibiogram, het onderzoek naar vaccL.J.S en het 
ontwikkelen van nieuwe middelen geen doorgang moet vinden. 
Hoofdstuk 1 
Geeft een historisch overzicht van de sexueel overdraagbare urethritiden. 
De verschlllende verwekkers worden besproken, de klinische beelden en de 
complicaties. Er wordt een overzicht gegeven van de verschillende therapieen door 
de jaren heen en de problemen die zich daarbij voordeden. De resistentie vorming 
van de veroorzakende micro-organismen wordt uitgebreid besproken. Er wordt 
ingegaan op de epidemiologie van gonorroe, C. trachomatis en NGU. 
In een literatuurstudie worden de nieuwe geneesrnlddelen bij de behandeling van 
gonorroe, de quinolonen en de derde generatie- en orale cephalosporinen bediscus-
sieerd wat betreft in vitro activiteit tegen N. gonorrhoeae, effectiviteit en bijwer-
kingen. Tevens werd een literatuurstudie verricht naar de nieuwe geneesmiddelen bij 
de behandeling van NGU en C. trachomatis infecties. 
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De quinolonen en nieuwe macroliden worden besproken wat betreft in vitro 
aktiviteit tegen C. trachomatis en U. urealyticum, effectiviteit en bijwerkingen. 
Hoofdstuk 2 
lu een dubbel-blind gerandomiseerd onderzoek werden 155 mannen lijdend aan 
een ongecompliceerde gonorroische urethritis behandeld met 200 mg (n=77) of 400 
mg (n=78) enoxacin, een nieuw quinoloon, in een eenmalige orale gift. 
De genezingspercentages in de met 200- en 400-mg behandelde groep patiffiten 
waren respectievelijk 90% en 92%. De MIC voor enoxacin van de in_ deze studie 
gelsoleerde N. gonorrhoeae stanunen varieerde van 0.015 tot 0.12 pg/ml. De diag-
nose postgonorroische urethritis werd gesteld bij 29 (42%) patienten behandeld met 
200 mg enoxacin en bij 19 (26%) van de met 400 mg enoxacin behandelde 
patienten. 
Bijwerkingen (misselijkheid, hoofdpijn en braken) traden op bij 2 (3%) van de 77 
patienten in de met 200 mg behandelde groep en bij 3 ( 4%) van de 78 patienten in 
de met 400 mg behandelde groep. 
Hoofdstuk 3 
In een gerandorniseerd vergelijkend onderzoek met 0.5 g cefodizime, 1 g 
cefodizime of 1 g cefotaxime werden in totaal 424 mannelijke en vrouwelijke 
patienten met een urogenitale en bijkomende oropharyngeale gonorroe behandeld. 
Met 0.5 g cefodizime (eenmalige intramusculaire gift) werden 89 mannen en 54 
vrouwen, met l g cefodizime 87 mannen en 52 vrouwen en met 1 g cefotaxime 86 
mannen en 56 vrouwen behandeld. 
De genezingspercentages waren 100% voor zowel de mannelijke als de 
vrouwelijke patienten behandeld met 0.5 g en 1 g cefodizime. 
Het genezingspercentage in de met 1 g cefotaxime behandelde groep patienten 
was 99% bij de mannen en 100% bij de vrouwen. De MICs voor cefodizime en 
cefotaxime van de gelsoleerde N. gonorrhoeae stammen varieerde van 0.004 tot 0.06 
flg/ml. C. trachomatis werd bij 15% van de patienten geYsoleerd voor behandeling 
en bij 13% na behandeling. Bijwerkingen bestaande uit misselijkheid, diarree, 
buik1'ijn, genitale candidiasis en pijn op de injectie plaats werden gezien bij 4% van 
de patienten behandeld met cefodizime. 
Bijwerkingen bestaande uit duizeligheid, genitale candidiasis, vermoeidheid en 
diarree traden op bij 4% van de patienten behandeld met cefotaxime. Aile 
bijwerkingen war en mild en van voorbi jgaande aard. Cefodizime en cefotaxime zijn 
veilige en effectieve geneesmiddelen voor de behandeling van ongecompliceerde 
gonorroe. 
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Hoofdstuk 4 
In een pilot-studie werden 10 mannelijke patienten met een ongecompliceerde 
uretbrale gonorroe behandeld met 1200 mg ceftetrame in een eemnalige orale gift. 
Negen van de tien patienten waren na behandeling genezen. De gevoeligheid van de 
gelsoleerde N. gonorrhoeae stammen voor Ro 19-5247, de actieve metaboliet van 
ceftetrame, varieerde van < 0.002 tot 0.12 J.lg/ml. 
C. trachomatis werd bij I patient zowel voor a1s na behandeling ge"isoleerd. 
Bijwerkingen traden niet op. Ceftetrame kan een effectief geneesmiddel zijn bij de 
behandeling van ongecompliceerde urogenitale gonorroe. 
Hoofdstuk 5 en 6 
Geven een beschouwing over resistentievonning van N. gonorrhoeae voor de 
nieuwe quinolonen en het bestaan van een kruisresistentie tussen de verschillende 
quinoloon derivaten. 
Hoofdstuk 7 
In deze studie worden de in vitro gevoeligheden bepaald van ciprofloxacin, 
enoxacin, fleroxacin, lomefloxacin, norfloxacin, ofloxacin en pefloxacin voor 10 
PPNG's, 10 non PPNG's, 10 CMRNG's, 3 N. gonorrhoeae stannnen met een 
verminderde gevoeligheid voor quinoloon derivaten en een TRNGJPPNG stam. 
De non PPNG, PPNG, CMRNG en TRNG/PPNG stannnen hadden een 
uitstekende gevoeligheid voor de geteste quinolonen. De N. gonorrhoeae stam.men 
met een verminderde gevoeligheid voor quinolonen lieten hogere MIC waarden zien. 
Hoofdstuk 8 
In deze studie werden 152 mannelijke patienten met een NGU behandeld met 300 
mg roxithromycin per dag gedurende 7 dagen. C. trachomatis werd bij 53 (35%) 
patienten en U. urealyticum bij 42 (28%) patienten uit de urethra ge"isoleerd. Na 
behandeling waren bij 49 (92%) van de 53 patienten met een positieve C. 
trachomatis kweek en bij 34 (81 %) van de 42 patienten met een positieve U. 
urealyticurn kweek de kweken negatief geworden. Klinische genezing werd bij 
gezien bij 137 (90%) patienten. 
Bijwerkingen, bestaande uit misselijkheid, opgeblazen gevoel in de bnik, 
hoofdpijn en vermoeidheid werden waargenomen bij 10 (7%) patienten. 
In bet tweede dee! van deze studie werden 78 mannelijke patienten behandeld met 
2 x 150 mg roxithromycin per dag gedurende 7 dagen. 
C. trachomatis werd bij 22 (28%) patienten en U. urealyticum bij 30 (38%) 
patienten uit de urethra gelsoleerd. Na behandeling waren aile C. trachornatis 
bveken negatief geworden. Bij 23 (77%) van de 30 patienten met een positieve U. 
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urealyticum kweek waren de kweken negatief geworden na behandeling. Klinische 
genezmg werd gezien bij 70 (90%) patienten. 
Bijwerkingen, bestaande uit misselijkheid en hoofdpijn traden op bij 3 (4%) 
patienten. De conclusie van deze studie was dat roxithromycin een goed altematief 
is voor tetracycline bij de behandeling van NGU. 
Hoofdstuk 9 
In een gerandomiseerde studie werd de klinische effectiviteit van ciprofloxacin 
vergeleken met doxycycline bij patienten lijdend aan NGU. V eertien dagen na 
behandeling werd geen pyuria meer waargenomen bij 30 van de 100 met cipro-
floxacin behandelde patienten; C. trachomatis werd geisoleerd bij 5 en U. 
urealyticum bij 8 patienten. In de met 100 mg doxycycline behandelde groep 
patienten (n~60) werd 14 dagen na behandeling bij 36 (60%) patienten geen pyuria 
meer waargenomen; U. urealyticum werd bij 6 patienten gelsoleerd. In de met 200 
mg doxycycline behandelde groep patienten (n~45) werd 14 dagen na behandeling 
bij 18 (40%) patienten geen pyuria meer waargenomen; U. urealyticum werd bij 2 
patienten gelsoleerd. Bijwerkingen waren mild en van voorbijgaande aard. 
Ciprofloxacin in een dosering van 1 g per dag gedurende 7 dagen is niet geschikt 
voor de behandeling van NGU. 
Hoofdstuk 10 
Deze studie beschrijft de gevoeligheid van de in hoofdstuk 9 geisoleerde C. 
trachomatis stammen voor ciprofloxacin, doxycycline en erytbromycine. Tevens 
vend serotypering plaats van verschillende stammen die voor behandeling en de 
stammen die voor en na behandeling werden gelsoleerd. De MICs van boven-
genoemde antibiotica waren in overeenstemming met die welke in de literatuur 
worden gemeld. 
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ABBREVIATIONS 
AIDS - acquired immunodeficiency syndrome 
B. ureolyticus - Bacteroides ureolyticus 
C. trachomatis - Chlamydia trachomatis 
CMRNG - chromosomally mediated resistant N. gonorrhoeae 
DEAE - diethylaminoethanol 
DGI - disseminated gonococcal infection 
E. coli - Escherichia coli 
HIV - Human Immunodeficiency Virus 
HLA - Human Leucocyt Antigen 
MBC - Minimum Bactericidal Concentration 
MIC - Minimum Inhibitory Concentration 
MTR -GENE - Envelope phenotype 
M. genitalium - Mycoplasma genitalium 
N. gonorrhoeae - Neisseria gonorrhoeae 
NGU - non-gonococcal urethritis 
NON-PPNG - non penicillinase-producing N. gonorrhoeae 
PID - pelvic inflammatory disease 
PPNG - penicillinase-producing N. gonorrhoeae 
SOA - sexueel overdraagbare aandoening 
STD - sexually transmitted disease 
TEM-1 type b-lactamase - type of extra-chromosomal DNA 
TetM - streptococcal tetracycline resistance detenninant 
T. pallidum - Treponema pallidum 
TRNG - Plasmid mediated tetracycline resistant N. gonorrhoeae 
WHO - World Health Organization 
CDC - Centers for Disease Control 

